

Regional Pulmonary Vasoreactivity

with special reference to nitric oxide, prostacyclin and body posture



**Karolinska
Institutet**

Danguolé Rimeika

2009

For the joy of work and knowledge

To Malin and Felix

ABSTRACT (ENG)

The primary aim of the study was to investigate possible mechanisms behind the improved arterial oxygenation in ventilator-treated patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) when turned into prone position. A secondary aim was to discover new knowledge of possible importance for treatment of patients with oxygenation problems in intensive care and during anesthesia.

Previous work have described a dominant blood flow in dorsal lung regions regardless of posture and a better matching of ventilation (V) and perfusion (Q) in prone vs supine posture. Perfusion and also V/Q ratios are more homogeneous in prone than in supine position. The hypothesis of the study was that differences in regional pulmonary vasoreactivity to the endogenous vasodilators nitric oxide (NO) and prostacyclin (PGI₂) may explain the improved gas exchange in severe lung disease during ventilator treatment in prone position.

Regional pulmonary vasoreactivity to NO and PGI₂, as well as effects of posture on distribution of regional pulmonary blood flow, were investigated in isolated human and porcine lung tissue and pulmonary arteries in vitro and in volunteers and patients in vivo.

Presently it was shown that expression of mRNA for endothelial NO synthase (eNOS) was higher in dorsal compared to ventral human lung regions. Ca²⁺-dependent NOS activity was higher in dorsal than in ventral regions of both human and porcine lungs. Relaxation of porcine pulmonary arteries in vitro by acetylcholine and bradykinin, endothelial-dependent vasodilators, acting via the NO / cGMP pathway was more potent in vessels from dorsal than from ventral lung regions. Furthermore, NOS inhibition by infusion of N^G-monomethyl-L-arginine (L-NMMA) redistributed blood flow from dorsal to ventral lung regions in healthy volunteers in supine position. Altogether these results strongly suggest a role for endogenous NO in regulation of regional pulmonary perfusion.

Inhalation of iloprost, a synthetic PGI₂ analogue, decreased arterial oxygen tension in healthy volunteers. Pulmonary perfusion was redistributed towards dependent lung regions in both supine and prone, whereas ventilation was redirected towards non-dependent lung regions in supine position, indicating increased mismatch of ventilation and perfusion. Prostaglandin synthesis inhibition by the non-selective cyclooxygenase (COX) inhibitor diclofenac did not affect pulmonary perfusion distribution or oxygenation in healthy subjects.

Patients subjected to left side thoracic surgery in lateral decubitus position with one-lung ventilation (OLV) were treated with non-selective COX-inhibition by diclofenac infusion. They had significantly lower shunt and better oxygenation as measured by alveolo-arterial oxygen difference than patients receiving placebo. The results suggest that a COX-related arachidonic acid metabolite attenuates pulmonary hypoxic vasoconstriction.

In conclusion the results strongly suggest a role for endogenous NO in regulation of regional pulmonary perfusion. PGI₂ is likely not involved in regulation of regional pulmonary perfusion during normoxia whereas it may be of importance during hypoxia. The present results may become of importance for patients with oxygenation problems in intensive care as well as during one-lung ventilation for thoracic surgery.

Keywords: Regional pulmonary perfusion, nitric oxide, prostacyclin, NOS-inhibition, COX-inhibition, shunt, one-lung ventilation.

ABSTRACT (SWE)

Huvudsyftet med aktuell avhandling var att undersöka vilka mekanismer i lungorna som ligger bakom den förbättrade syresättningen av blodet hos svårt lungsjuka respiratorbehandlade patienter när de vänds i bukläge. Ett andra syfte var att söka efter ny kunskap som skulle kunna vara av betydelse för patienter med syrebrist inom intensivvård och under operationer.

Tidigare forskning har visat att en dominerande del av lungblodflödet går till ryggnära lungdelar oavsett kroppsposition, dvs. både i rygg- och bukläge. Anpassningen mellan luft- och blodflöde har också visats vara mer optimal i bukläge. D.v.s. blodet går i större utsträckning till lungdelar där det finns gott om syre. Hypotesen i studien var att de kroppsegna blodkärlsvidgande ämnena kväve monoxid (NO) och prostacyclin (PGI₂) kunde förklara den förbättrade syresättningen av blodet i lungorna vid svår lungsjukdom under respiratorbehandling i bukläge.

Avhandlingen beskriver studier av reglering av regionalt lungblodflöde av de två ämnena NO och prostacyclin PGI₂, som båda bildas i de celler som täcker insidan av kroppens blodkärl (endotelceller). Effekter på blodflödets fördelning i lungorna beroende på kropps läge (rygg-, buk- och sidoläge) undersöktes också.

Det visades att genetisk information (mRNA) för proteinet som bildar NO i endotelceller, endoteliellt NO syntas (eNOS) fanns i större koncentration i ryggnära lungregioner. Calcium-beroende NO syntas som finns i kärlendotel och nervceller hade högre aktivitet i ryggnära lungdelar än bröstnära hos både människa och gris. Vid hämning av NO-bildning via blockering av NO-syntas omfördelades lungblodflödet i rygg läge hos friska försökspersoner från ryggnära till bröstnära lungregioner. Undersökning av isolerade kärl i så kallade organbad visade även större kärlvidgning i de ryggnära kärlen jämfört med de bröstkorgsnära när de stimulerades med ämnen som verkar via NO. Detta talar för att NO bildat i lungorna har betydelse för regleringen av regionalt lungblodflöde.

Inandning av syntetiskt prostacyclin sänkte syrehalten i blodet på friska försökspersoner. (Hos lungsjuka brukar vanligen blodets syrehalt stiga.) Lungblodflödet omfördelades mot lågt liggande lungregioner både i rygg- och bukläge, d.v.s. effekten av gravitationen förstärktes. Luftflödet omfördelades i rygg läge mot högt liggande lungdelar, dvs. i motsatt riktning mot blodflödet, vilket skulle kunna leda till försämrad matchning av blod och luftflöde och därmed bidra till den sänkta syrehalten i blodet hos lungfriska. Hämning av bildning av kroppsegna prostaglandiner (tex. prostacyclin) med en cyclooxygenashämmare (diklofenak) påverkade inte blodflödesfördelning eller syresättning hos friska.

Patienter som opererades i vänster lunga med ventilation av endast den icke-opererade lungan (enlunds ventilation) fick förbättrad lungblodflödesfördelning vid behandling med diklofenak jämfört med patienter som fick icke verksam behandling (koksalt). Vid avstängning av en lunga uppstår syrebrist i denna och blodet styrs då över till den luftfyllda lungan för att blodets syresättning ska bli så effektiv som möjligt (syrebrist-utlöst kärlsammandragning). Våra resultat tyder på att denna kroppsegna skyddsreflex förstärktes pga hämning av en prostaglandinlik substans (t.ex. prostacyclin) som motverkar den syrebristutlösta kärlsammandragningen.

Sammanfattningsvis tyder resultaten på att kroppseget NO har betydelse för reglering av regionalt lungblodflöde. Kroppseget prostacyclin är sannolikt inte inblandat i reglering av regionalt lungblodflöde hos friska med normal syrehalt i lungorna medan det kan ha betydelse vid syrebrist. Resultaten kan ge uppslag till nya behandlingsalternativ för patienter med syrebrist inom intensivvård samt vid operationer med enlunds ventilation.

CONTENT

LIST OF PAPERS.....	9
ABBREVIATION INDEX.....	11
INTRODUCTION.....	13
General pulmonary perfusion.....	13
Regional pulmonary perfusion.....	14
Pulmonary vasoregulation.....	15
Nitric oxide (NO)	17
Prostaglandin I ₂ (PGI ₂).....	18
Posture.....	19
AIMS.....	21
SUBJECTS, MATERIALS AND METHODS.....	23
Subjects.....	23
Patients.....	23
Volunteers.....	23
Animals.....	23
Investigational methods.....	24
Real time polymerase chain reaction (PCR) for mRNA eNOS quantification (paper I).....	24
Citrulline assay for NOS-activity (paper I and II).....	24
Organ bath experiments for vasoreactivity studies in isolated pulmonary arterial ring preparations (paper II).....	24
SPECT-single photon emission computed tomography for pulmonary perfusion or ventilation studies (paper I and III).....	25
Clinical investigation with shunt calculations during unilateral hypoxia (paper IV).....	27
Study protocols.....	27
Pharmaceutical interventions.....	27
Anesthesia.....	27
Patients.....	27
Volunteers.....	28
Animals.....	28
Statistics.....	28
Ethical considerations.....	28
RESULTS.....	29
Differences in vasoreactivity between ventral and dorsal lung regions with reference to nitric oxide. (Paper I, II).....	29
NOS-inhibition, regional pulmonary perfusion and arterial oxygenation in vivo, healthy humans (Paper I)	30
Differences in regional pulmonary perfusion and arterial oxygenation with reference to prostaglandins in healthy humans. (Paper III).....	33
Differences in pulmonary perfusion with reference to prostaglandins during regional hypoxia in vivo. (Paper IV).....	35

DISCUSSION.....	39
Are there regional differences in pulmonary vasoreactivity to nitric oxide?	39
Can differences in regional pulmonary vasoreactivity play a role in regional lung blood flow distribution with reference to posture?.....	40
Are there regional differences in pulmonary vasoreactivity to prostacyclin?.....	41
Vasoactive drugs, hypoxic pulmonary vasoconstriction and regional pulmonary perfusion.	42
What are the clinical implications of the findings in this thesis?.....	43
CONCLUSIONS	45
ACKNOWLEDGEMENTS.....	47
REFERENCES.....	49
PAPERS I-IV	

LIST OF PAPERS

This thesis is based on the following papers, which will be referred to in the text by their Roman numerals:

- I. Rimeika D, Nyrén S, Wiklund NP, Renström Koskela L, Törring A, Gustafsson LE, Larsson SA, Jacobsson H, Lindahl SGE, and Wiklund CU.
Regulation of regional lung perfusion by nitric oxide.
American Journal of Respiratory and Critical Care Medicine 2004; **170**: 450-455
- II. Rimeika D, Wiklund NP, Lindahl SGE, and Wiklund CU.
Regional differences in nitric oxide-mediated vasorelaxation in porcine pulmonary arteries.
Acta Anaesthesiologica Scandinavica 2006; **50**: 947-953
- III. Rimeika D, Sanchez-Crespo A, Nyren S, Lindahl SGE and Wiklund CU.
Iloprost inhalation redistributes pulmonary perfusion and decreases arterial oxygenation in healthy volunteers.
Acta Anaesthesiologica Scandinavica 2009; **53**: 1158-1166
- IV. Rimeika D, Lindahl SGE and Wiklund CU. (2009)
Non-selective cyclooxygenase (COX) inhibition decreases shunt during one lung ventilation for thoracic surgery.
Submitted for publication.

ABBREVIATION INDEX

ALI	Acute Lung Injury
ARDS	Acute Respiratory Distress Syndrome
CI	cardiac index (=cardiac output/body surface)
CMV	controlled mechanical ventilation
EELV	end-expiratory lung volume (=FRC)
FIO ₂	inspired fraction of oxygen
FRC	functional residual capacity
HPV	hypoxic pulmonary vasoconstriction
L-NMMA	N ^G -monomethyl-L-arginine
NO	nitric oxide
NOS	nitric oxide synthase
NSAID	non steroidal anti-inflammatory drugs
PASMC	pulmonary arterial smooth muscle cells
P (A-a) O ₂	alveolo-arterial oxygen tension difference
PaO ₂	arterial oxygen tension
PaCO ₂	arterial carbon dioxide tension
PaO ₂ / FIO ₂	arterial oxygen tension/inspired fraction of oxygen
PBF	pulmonary blood flow
PEEP	positive end-expiratory pressure
PGI ₂	prostacyclin
PVR	pulmonary vascular resistance
Q	lung perfusion
SPECT	single photon emission computed tomography
SvO ₂	mixed venous oxygen saturation
TLC	total lung capacity
V	ventilation
V/Q	ventilation perfusion ratio

Pressure units conversion formula: 101.3 kPa = 760 mm Hg (Torr) = 1 atm.

INTRODUCTION

During the last half-century a striking development has occurred within the medical and technical fields of Intensive Care Medicine. Despite increased possibilities to provide more advanced and gentle mechanical ventilatory support¹⁴⁶, mortality is still high, between 30 and 50%, for patients subjected to ALI or ARDS^{19, 76, 86, 91, 121}. The substantial number of patients dying from hypoxia in spite of adequate cardiac function strongly marks the need of increased knowledge in pulmonary pathophysiology. Continued research about mechanisms governing gas exchange is required.

Extracorporeal oxygenation offers an ultimate therapeutic strategy. It is an advanced rescue therapy which is, due to high costs limited to a small number of patients, especially in times of economical strain. However, early initiated position treatment is cost effective and feasible even in smaller Intensive Care Units, and has been shown to improve arterial oxygenation^{5, 24, 39, 100}, in 65-75 % of the patients turned into prone position^{28, 50, 57, 73, 87, 112, 159}. In spite of the improvement in oxygenation no randomized clinical trials have shown improved survival by ventilator treatment in the prone position. Post hoc analysis of subgroups suggest that mortality may be reduced in patients with severe ARDS and there is also a tendency towards lower mortality when prone position treatment is initiated early^{50, 87, 137, 160}. Nevertheless, the question still remains concerning the causative mechanisms behind the improved oxygenation. During the last decades there has been a consistency in literature that prone position provides a more homogenous ventilation and perfusion ratio^{7, 99, 129}. But why are perfusion and ventilation distributions better matched in the prone position? Suggested mechanisms are increased FRC¹¹³, decreased vertical pleural pressure gradient^{102, 147} a more evenly distributed lung tissue due to less compression by the mediastinal and abdominal structures^{4, 118, 124}, more homogenous regional ventilation/perfusion ratios due to basic vascular anatomical structure^{7, 52, 55} and higher vascular conductance in dorsocaudal lung regions¹⁴, recruitment of dorsal atelectatic lung units⁸¹, regional changes in ventilation due to alterations in chest wall mechanics^{23, 112} or increased secretion drainage in the prone position. Enhanced understanding, how to optimize the complex ventilation / perfusion matching in the lung, might extend the treatment strategies for the clinicians challenged by severe hypoxic patients.

This thesis will chiefly discuss mechanisms regulating blood flow distribution in the lung, with special reference to vasoreactivity and posture. Distribution of ventilation and V/Q-ratios will not be discussed in detail.

General pulmonary perfusion

The lung possesses a low resistance circulation that must, at all times, accommodate the entire cardiac output. Moreover, to ensure adequate oxygenation of haemoglobin, blood flow must be directed to well-ventilated lung units, i.e., ventilation and perfusion must be matched⁴⁸. One remarkable characteristic of the low pressure pulmonary circuit is its capacity to decrease pulmonary vascular resistance (PVR) as pressure within the system rises. Two mechanisms are responsible for this: recruitment and distension of vessels. Another unique feature of the pulmonary circulation is that vessels are exposed to different distending forces as lung volumes expand and diminish above and below functional residual capacity. As a result, the diameter and length of the vessels are passively influenced by changes in lung volume, at the same time as there are numerous active

neurogenic, chemical and humoral factors governing the vascular diameter⁴⁸. Total lung blood flow is also influenced by the cardiac function and changes in pulmonary blood volume.

All interrelated mechanical and chemical factors governing pulmonary blood flow contribute to the complexity of pulmonary physiology and challenge the clinician to make the right decisions to optimize ventilation / perfusion matching. When comparing investigations concerning distribution of pulmonary blood flow, there are many factors in a study design that may influence the results. For instance, spontaneous breathing versus positive pressure ventilation; awake subjects versus anesthetized with muscular relaxation; in vitro versus in vivo conditions will all have great impact on the pulmonary perfusion (and ventilation) distribution^{17, 48, 64, 145, 148}.

Regional pulmonary perfusion.

The distribution of pulmonary blood flow is chiefly governed by the distensibility of vessels and their transmural distending pressure⁴⁸. It is now apparent that although gravity does have a measurable influence on pulmonary blood flow (PBF) distribution, the anatomic structure of the arterial tree plays a prominent role in the distribution of PBF^{49, 52, 55, 66}, which will be discussed below. Since the 1960's, when West introduced the zonal model based on the relationship between pulmonary arterial, alveolar and venous pressures, gravity has been considered the predominant factor for regional pulmonary perfusion and ventilation distribution. Studies using radioactive gases and external scintillation counters on isolated, perfused, animal lungs showed a greater regional blood flow to the dependent (bottom) regions^{125, 162}. Later investigations on humans confirmed these findings, and gravity was considered as the most important determinant of lung blood flow distribution⁸⁴. Recent research, however, with high resolution technology using fluorescent microspheres, has shown considerable blood flow heterogeneity within iso-gravitational planes^{51, 52, 53, 65, 155}, findings that cannot be explained by the zonal model based on the influence of gravity. In animal studies Glenny et al used the redistribution of pulmonary blood flow at a change in posture to demonstrate that the effect of gravity is minor in proportion to overall variation in regional blood flow⁵³. Later, SPECT investigations of pulmonary ventilation and perfusion in humans have confirmed that gravity is of less importance in the prone and supine positions, but has greater influence in the upright position^{7, 119}. In microgravity environment, i.e. space experiments, the blood flow heterogeneity remains which confirm that gravity is a minor determinant of regional lung blood flow distribution^{54, 123}. During hypergravity conditions at 5G, on the other hand, there is a redistribution of blood flow in opposite direction to the gravitational force¹¹⁷. Altogether, these results have lead to the challenging assumption that the basic anatomical structure of the pulmonary vascular tree is an important determinant of regional blood flow⁶⁶.

In 1986, Beck and Rehder demonstrated regional differences in vascular conductance in isolated dog lungs¹⁴, which raised the postulate that there might exist differences in regional vasoreactivity in the lung. This hypothesis was further strengthened by a study by Pelletier et al., 1998, which showed differences in vasoreactivity to various vasorelaxing agents in isolated dorsal and ventral equine pulmonary arterial rings¹¹¹.

In 1946, Euler showed that regional hypoxia could divert pulmonary blood flow away from poorly ventilated lung units with inadequate oxygenation to better ventilated regions¹⁶³. This unique behaviour to hypoxia in the pulmonary vessels, called the hypoxic pulmonary vasoconstriction (HPV), provides an important mechanism for maintaining optimal ventilation / perfusion matching and improves arterial oxygenation^{18, 90, 161}. There are numerous local vasoactive substances that modulate HPV^{46, 138} and thereby play an indirect role for regulation of regional pulmonary blood flow. Posture may also affect blood flow diversion by HPV¹⁵⁴. If there exist regional differences in

sensitivity to hypoxia in the lungs has to be further investigated in this work. In this thesis we have focused on vasorelaxing substances acting via the NO /cGMP or the PGI₂ /cAMP pathways.

Pulmonary vasoregulation

The pulmonary circulation is unique in that it must, at all times, accept the entire cardiac output and yet, despite large and variable blood flows, direct the blood flow to well-oxygenated regions. Thus, the regulation of pulmonary vascular tone is complex with a balance between local vasoconstricting factors directing blood flow to well-oxygenated lung units and on the other hand, vasorelaxing factors that must maintain a low resistance in the pulmonary circuit to protect the right ventricle that cannot tolerate a high after-load. The pulmonary vascular resistance (PVR) is normally kept at approximately one-tenth of the systemic vascular resistance.

Table 1. Factors that alter Pulmonary Vascular Resistance

Increased PVR	Decreased PVR
Active	
Sympathetic stimulation	Nitric oxide
Hypoxia	Prostaglandins (PGI ₂ ,PGE ₂)
Hypercapnia	Acetylcholin
Acidosis	Bradykinin
Catecholamines	Isoproterenol
Angiotensin II	Theophylline
Endotelin-I	Phosphodiesteras inhibitors
Histamin (H1)	
Prostaglandins (D ₂ ,E ₂ ,F ₂)	
Substance P	
Leukotrienes	
Seretonin	
Passive	
Lung inflation or deflation from FRC	Increased cardiac output
Increased perivascular pressure	Increased P _{pa} and P _{la}
Increased blood viscosity	Increased pulmonary blood volume

Changes in PVR can be caused by active or passive factors ¹¹. Active changes are accomplished by neurogenic, chemical and humoral factors, while passive changes in PVR imply alteration in vessel calibre in response to factors such as lung mechanics or hemodynamics (where posture, gravity and vascular structure play a role). Some of these factors are listed in (table 1) ⁴⁸.

Active forces alter PVR and tone, and hence the distribution of pulmonary blood flow, by causing contraction or relaxation of vascular smooth muscle ¹¹. An increase in tone will occur if any of these factors

directly or indirectly increases the cytosolic Ca²⁺-concentration to more than 10⁻⁶ mol l⁻¹.

Ca²⁺-ions then bind to calmodulin (CaCM)

a) which activates myosin light chain kinase (MLCK). The active 4Ca²⁺-CM-MLCK complex phosphorylates myosin and enables interaction with actin leading to muscle contraction.

b) bind to caldesmon, which then detaches from the actin tropomyosin complex, thus making it available for filament sliding.

Direct phosphorylation of caldesmon by protein kinase C also seems to induce filament sliding and contraction.

On the other hand, factors causing a decrease in intracellular Ca²⁺-concentration to less than 10⁻⁶ mol l⁻¹ or activates phosphatase induce relaxation. Also, direct activation of protein kinase C stimulates myosin light chain kinase which then phosphorylates myosin regulatory light chain leading to Ca²⁺-desensitization of myofilament and thereby relaxation of the smooth muscle.

Increased cytosolic levels of cGMP or cAMP is one of the major mechanisms mediating vasodilation under physiologic conditions. cGMP mediates the action of endogenous vasodilators such as NO, carbon monoxide (CO) and natriuretic peptides ¹⁵¹ via inhibition of phosphodiesterases, activation of soluble and membrane bound guanylyl cyclase. An increase in cGMP activates protein kinase G, leading to decrease in cytosolic Ca²⁺-concentration via uptake in the sarcoplasmic re-

ticulum and inhibition of voltage-operated calcium channels (VOCC) and thereby causes relaxation. cAMP activates protein kinase A, which inhibits phospholipase C and VOCC, stimulates Ca^{2+} uptake in the sarcoplasmic reticulum and thereby decrease cytosolic Ca^{2+} -concentration leading to relaxation⁹⁵. Furthermore cAMP and cGMP reduces myofilament Ca^{2+} -sensitivity (Fig. 1).

For the most part, vasoactive substances have similar effects on pulmonary and systemic vessels. However, there are some important exceptions; hypoxia, hypercapnia and acidosis produce vasodilatation in the systemic circuit whereas these factors produce vasoconstriction in the pulmonary circulation. One primary physiological determinant of vascular resistance in lung is alveolar pO_2 ^{61, 98}. The unique behaviour of the pulmonary vascular smooth muscle cells in response to hypoxia is an




Figure 1 Schematic overview of the proposed mechanisms for a) vasorelaxation mediated by the endothelium dependent eNOS / NO / guanylate cyclase/ cGMP and COX / prostacyclin / adenylate cyclase / cAMP pathways. b) pulmonary vasoconstriction induced by hypoxia.

For details see text page 15. Plus sign = stimulation; minus sign = inhibition, question mark = not established.

Ach = acetylcholine, Bk = bradykinin, NO = nitric oxide, eNOS = endothelial nitric oxide synthase, PGI₂ = prostacyclin, NADPH = dihydro-nicotinamid-adenine-dinucleotide phosphate, PKG = protein kinase G, PKA = protein kinase A, PKC = protein kinase C, SR = sarcoplasmic reticulum, ATP = adenosine 5'-triphosphate, cAMP = cyclic adenosine- 3', 5'-monophosphate, GTP = guanosine 5'-triphosphate, cGMP = cyclic guanosine 3', 5'-monophosphate, IP₃ = inositol 1'4'5'-triphosphate, PASMC = pulmonary arterial smooth muscle cells

The unique behaviour of the pulmonary vascular smooth muscle cells in response to hypoxia is an adaptive vasomotor response of resistance pulmonary arteries, aimed to divert blood from poorly oxygenated areas to better ventilated lung segments thus improving ventilation-perfusion matching and thereby reducing shunt fraction and optimizing PaO₂^{88, 144, 163}. HPV is intrinsic to the lung and, although modulated by the endothelium, the core mechanism is in the smooth muscle cells. The exact mechanism for HPV is still elusive¹⁶¹. The Redox Theory proposes that HPV results from a coordinated action of a redox-based sensor (proximal mitochondrial electron transport chain) which generates a diffusible mediator, a reactive O₂ species (ROS) that regulates effector proteins. Hypoxic modulation of ROS leads to inhibition of the specific O₂-sensitive voltage-gated potassium channels (Kv1.5 and Kv2.1), leading to depolarization of pulmonary artery smooth muscle cells, activation of L-type voltage-gated calcium channels, which increases calcium influx and initiates vasoconstriction^{93, 98, 127}. The exact time course of HPV is still under debate in the literature. However, the onset of HPV is immediate (in seconds), seems to be biphasic with a first endothelium independent culmination in 10-15 minutes and then a second endothelium dependent increase after 30-40 minutes^{88, 98} with sustained, or even increased effect for hours^{72, 142} or until reoxygenation occurs³⁶. The sustained response seems to be endothelium dependent and is thus subjected to modulation by endothelium derived vasoactive substances. Vasorelaxing substances like nitric oxide and prostacyclin have been shown to decrease the HPV response via mechanisms not fully known^{46, 138}.

The principal stimulus for HPV is alveolar hypoxia, whereas decreased mixed venous oxygen tension is only a contributory factor. Marshall and Marshall 1980 showed that the magnitude of blood flow diversion is related to the size of the hypoxic lung segment⁸⁸. If the hypoxic part equals one lung, for instance during one-lung ventilation, numerous clinical studies have found that shunt in the non-ventilated lung is usually 20-25% of the cardiac output as opposed to the 40-60% shunt that might be expected if there was no HPV^{17, 18}. In case of global hypoxia, there will be an increase in pulmonary arterial pressure due to general vasoconstriction, instead of PBF diversion.^{17, 18, 88, 148} There has also been demonstrated heterogeneity in HPV response in porcine lungs which partly may explain high-altitude pulmonary oedema⁶⁷.

In the present thesis we have focused on the potent pulmonary vasodilators nitric oxide and prostaglandin I₂ to investigate their role in regulation of *regional* pulmonary perfusion, during both normoxia and hypoxia. The influence of posture on regional perfusion distribution has also been a subject of our interest. By altering posture there will be a change in PVR due to influence of passive mechanical factors, as discussed earlier, which might interact with the effects of local vasoactive substances. It is difficult to identify the precise contribution of each of these factors to regulation of regional pulmonary blood flow. They are often interrelated, so a change in one affects a change in another; which adds to the complexity of pulmonary pathophysiological research.

Nitric oxide (NO)

In 1980, Furchgott and Zawadzki observed that intact endothelium was mandatory for induction of arterial relaxation by acetylcholine⁴⁷. This endothelium-dependent vasorelaxation was later shown to be due to production of NO⁷¹. NO is produced by oxidation of L-arginine to citrulline, catalyzed by the enzyme NO-synthase (NOS)¹¹⁰. NO-synthase exists in three isoforms; two Ca²⁺ and calmodulin requiring constitutive enzymes found in neural tissue (nNOS) and in vascular endothelial cells (eNOS), and a Ca²⁺-independent inducible enzyme (iNOS) isolated from macrophages, vascular smooth muscle cells and neutrophils¹⁵⁷. NO can also be produced non-enzymatically by direct reduction of nitrite during acidotic or ischemic conditions¹⁶⁴.

Substances like acetylcholine and bradykinin cause an increase of intracellular free calcium concentration in the endothelium activating NOS and stimulating NO production^{62, 85}. NOS is only modestly expressed in the pulmonary vessels in normal lung, suggesting a limited role in maintaining low basal tone⁴⁰. However, it is markedly up regulated in response to hypoxia or inflammation, thus playing a central role in modulating the response to pulmonary vasoconstrictor stimuli such as hypoxia⁶² and to local vasoconstrictors like angiotensin-II, endothelin-I or thromboxane A₂ (TXA₂)^{115, 136}. Increased vascular shear stress¹²⁰ and mechanical factors like stretching¹¹⁶ are also known to be potent stimuli for endothelial NO synthesis.

NO is a potent pulmonary vasodilator, relaxing precapillary resistance vessels to a greater degree than the large capacitance vessels⁴⁴. It diffuses freely over the cell membrane, activates guanylyl cyclase leading to increased levels of cGMP and thereby a decrease in intracellular free calcium concentration in the pulmonary vascular smooth muscle cell and thus vasorelaxation^{34, 96, 149}. NO is short-lived with a biological half-life of 2 – 30 seconds. It rapidly and avidly binds to haemoglobin and forms nitrosylhemoglobin and methemoglobin³². NO binds to and is inactivated by haemoglobin before it can reach the systemic circulation, which makes it suitable as a selective pulmonary vasodilator when inhaled⁴⁶. NO synthesis can be blocked by using competitive inhibitors to the substrate L-arginine which binds to a specific site on the activated NO-synthase^{96, 68}.

Besides regulation of vascular tone, NO is involved in a variety of biological processes. In the lung, NOS is expressed in airway epithelial cells, in macrophages, mastcells, neutrophils, smooth muscle cells, fibroblasts and platelets^{56, 141}.

Prostaglandin I₂ (PGI₂)

Prostacyclin is one among a number of prostaglandins synthesised in the lung. Prostaglandins, a group of the eicosanoid family, have an important role in regulation of pulmonary vascular and bronchial tone. They also have important anti-inflammatory actions and modify platelet aggregation^{63, 75}. The prostaglandins are derived from the cyclooxygenase (COX) metabolism of arachidonic acid, a component of membrane phospholipids¹⁵⁶. There are two isoforms of the enzyme cyclooxygenase, COX-I being constitutively expressed, and COX-2, which is induced in inflammatory processes^{63, 132}. The various prostaglandins have potent, often opposing actions in the pulmonary vasculature and airways, for instance PGD₂, PGE₂ and PGF_{2α} as well as TXA₂ elicit vasoconstriction, while PGI₂ (prostacyclin) and PGE₁ cause vasodilation⁷⁵. The most important pulmonary cell type responsible for the synthesis of cyclooxygenase products is the vascular endothelial cell, and the preferentially synthesised product is prostacyclin. Prostacyclin is a potent pulmonary vasodilator with a half-life of 4 minutes, and biological effect of 20-30 minutes. It acts via stimulation of the adenylyl cyclase / cAMP pathway, thus decreasing the intra-cellular calcium concentration and thereby initiating vasorelaxation. Prostacyclin is metabolised by beta-oxidation in the liver^{63, 132}. PGI₂ production can be up regulated via increases in blood flow, shear stress^{45, 131} and hypoxia⁶⁰. Aspirin and non-steroidal anti inflammatory drugs (NSAIDs) are analgesic and anti-inflammatory by virtue of inhibition of the cyclooxygenase mediated biosynthesis of prostaglandins. The efficacy and selectivity of the COX-inhibiting effect depends on dose and drug properties. Among the non-selective COX-inhibitors, indomethacin and ipobrufen inhibit both the synthesis of prostacyclin and TXA₂, while diclofenac seems to have less effect on the TXA₂ synthesis²⁷.

As compared with nitric oxide, prostacyclin has a variety of effects in the lung. Besides modulation of vascular tone, prostacyclin inhibits platelet aggregation and smooth muscle cell proliferation, effects that can be of importance in treatment of pulmonary hypertension^{105, 107, 69}.

Posture

During the latest two decades many investigations have demonstrated better oxygenation in hypoxic and ventilator treated patients, when treated in the prone position.^{24, 28, 39, 50, 57, 73, 87, 100, 112, 159}

Several investigations have shown more homogenous ventilation / perfusion ratios in prone compared to supine position during mechanically ventilation^{7, 99, 129}. Perfusion and ventilation are more uniform in prone compared to supine position most likely depending on several factors discussed above. In the upright lung, Wests zonal model explains the gravity-influenced relationship, and therefore posture, between the intravascular hydrostatic pressures and the vertical height of the lung. In zone 1 the regional pulmonary arterial pressure (P_{pa}) is lower then the alveolar pressure (P_{alv}) which results in no blood flow in the capillaries surrounding the alveoli. In zone 2 P_{pa} is above but pulmonary venous pressure (P_v) below P_{alv} which results in an increasing vertical gradient in blood flow down this zone. In zone 3 $P_{pa} > P_v > P_{alv}$ resulting in maintained blood flow but decreased alveolar size¹⁶². Several investigators in recent studies with high resolution techniques have confirmed an increased blood flow to dependent regions, due to the vertical pressure gradient, in upright position^{70, 84, 119}. Glenny showed 1999 that gravity explained 25% of the blood flow heterogeneity in upright baboons, but only 7% and 5% in the supine and prone postures respectively⁵¹. It should be kept in mind that in supine position, left atrial pressure is 10 cm H₂O in healthy subjects, resulting in an extension of zone 3 to 10 cm above the center of the left atrium, which includes most of the lung height in prone and supine position. However, positive pressure ventilation might induce zone 2 conditions also in horizontal posture. Therefore the posture has limited effect on ventral-to-dorsal distribution of blood flow in prone and supine postures¹¹⁸. When analysing results from investigations of regional pulmonary perfusion distribution indifferent postures, it is important to relate alterations in perfusion distribution to changes in tissue redistribution^{118, 124}.

During the last decades the Seattle group has shown convincing data that the anatomical structure with fractal branching of the vascular and bronchial tree is the most important determinant of distribution of ventilation and perfusion^{52, 55, 66}. The structure of the vascular tree is suggested to explain 64% of the more homogenous PBF distribution in the prone position⁷. These findings do not exclude coexisting differences in regional vasoreactivity of importance for regulation of pulmonary perfusion.

Could the optimized ventilation/perfusion matching in prone position reflect an adaptive evolutionary mechanism from the quadruped stage? Structure as well as regional vasoreactivity in the lung might have developed during millions of years to counteract the effect of gravity on ventilation/perfusion distribution.

AIMS

General aims

The majority of ventilator treated patients in intensive care units, suffering from Acute Lung Injury, ALI, improve gas exchange when turned prone. The overall purpose of this thesis was to reach new knowledge of importance for better understanding of mechanisms behind the improved gas exchange in prone position. The final goal was to explore new knowledge of possible use to improve treatment of patients with life-threatening lung disease in intensive care.

Specific aims were to find out if:

- expression of mRNA for endothelial nitric oxide synthase (eNOS) is different in ventral and dorsal lung regions in humans **(I)**
- Ca^{2+} -dependent and Ca^{2+} -independent NOS activity is different in ventral and dorsal lung regions in humans **(I)**
- lung perfusion in ventral and dorsal lung regions is influenced by inhibition of NO synthesis **(I)**
- production of NO, in pigs, is different in ventral and dorsal lung regions **(II)**
- endothelium dependent mediators like acetylcholine and bradykinin act differently on ventral and dorsal pulmonary arteries in pigs **(II)**
- eicosanoids are involved in regulation of regional pulmonary perfusion in healthy humans **(III)**
- inhibition of prostaglandin synthesis decrease shunt fraction in the lungs during one-lung ventilation for thoracic surgery **(IV)**

SUBJECTS, MATERIALS AND METHODS

The methods have been described in detail in paper I-IV. Below follows a description of the methods more in general.

Table 2. Methods, total number of patients, volunteers and animals are given. Types of investigational methods are shown

Paper			No.of	No.of	No.of
No	Methods	Investigation	Patients	Volunteers	Animals
I	SPECT	Effect of NOS-inhibition on pulmonary perfusion in different body postures in healthy humans		9	
I	PCR	eNOS mRNA	13		
I, II	Citrulline assay	Ca ²⁺ -dependent NOS-activity	21		18
II	Experimental organ bath	Vasoreactivity			20
III	SPECT	Effect of prostacyclin inhalation and COX-inhibition on pulmonary perfusion in different body postures in healthy humans		19	
IV	Clinical trial	Effect of COX-inhibition on pulmonary perfusion during hypoxia	32		

Subjects

Patients

Altogether 53 patients were studied. In **paper I** there were 9 males and 12 females with mean age 69 years (range 41-92) subjected to lung biopsies. All 21 were investigated by analysis of NOS activity, 13 of those were also investigated by analysis of eNOS mRNA. In **paper IV** there were 11 men and 21 females with mean age 65 (range 36-81). They were all scheduled for lung surgery because of diagnosed or suspected pulmonary malignancy. Exclusion criterias were occurrence of other pulmonary disease or use of corticosteroids, acetyl salicylic acid or non-steroidal anti-inflammatory substances.

Volunteers

Altogether 28 non-smoking healthy volunteers participated. In **paper I** there were 5 males and 4 females, mean age 31 years (range 23-47) and in **paper III** there were 9 males and 10 females, mean age 29 years (range 21- 45) studied.

Animals

In **paper II** twenty pigs specially bred for research, weighing 18.5-22.5 kg were studied. They were 18-22 weeks old.

Investigational methods

Real time polymerase chain reaction (PCR) for mRNA eNOS quantification (paper I)

Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and quantified by spectrophotometry. Two micrograms of total RNA were used for cDNA synthesis. Approximately 50 ng of cDNA was amplified by real time polymerase chain reaction using primers and probes as described in (Table 3). Samples were analyzed in duplicate, and polymerase chain reaction amplification was correlated against a standard curve. eNOS mRNA expression was quantified in relationship to mRNA expression of β -actin, selected as a housekeeping gene.

Table 3 Target primers and probes used for real-time polymerase chain reaction

Target Gene	Sequences (5'-3')
eNOS	Primer forward GCAACGCTACCACGAAGACAT
	Primer reverse CGGCTTGTCACCTCCTGG
	Probe TCGGGCTCACGCTGCGCA
β -Actin	Primer forward CTGGCTGCTGACCGAGG
	Primer reverse GAAGGTCTCAAACATGATCTGGGT
	Probe CCTGAACCCCAAGGCCAACCG

Definition of abbreviation: eNOS = endothelial nitric oxide synthase.

Citrulline assay for NOS-activity (paper I and II)

The conversion of l-(U-14C) arginine to l-(U-14C) citrulline was used for measurement of NOS activity as previously described (**paper I, II**)^{97, 133}. The analysis was performed in the presence or absence of the calcium chelator ethyleneglycol-*bis*-(aminoethyl ether)-*N, N*-tetra acetic acid (EGTA) to differentiate between Ca^{2+} -dependent and Ca^{2+} -independent NOS activity.

Organ bath experiments for vasoreactivity studies in isolated pulmonary arterial ring preparations (paper II)

During anesthesia with spontaneous breathing the porcine heart and lungs were harvested, immediately chilled in ice-cold physiological salt solution (PSS) and dissected on ice. Preparations of vascular rings from ventral and dorsal porcine pulmonary arteries were mounted vertically between two stainless steel hooks. The hooks were attached by silk sutures and arranged vertically between a stationary hook and a force transducer in 25 ml organ bath in PSS at +4°C. The organ bath was continuously aerated with 5% CO_2 in oxygen. The isometric tension generated in the vessel rings was continuously recorded on a multi channel Grass polygraph. Ring preparations were given an initial isometric load of 5 mN. The PSS temperature was raised to +37°C over 60 minutes and the rings were then equilibrated for another 60 minutes before start of the experiment.

Sub maximal contraction was achieved with norepinephrine 10^{-6} M and cumulative dose-response curves for bradykinin, acetylcholine and nitroprusside were studied. NO-mediated relaxations were inhibited with L-NMMA, while diclofenac was used to inhibit possible prostacyclin mediated relaxations. The antagonism by L-NMMA or diclofenac was reversed by L-arginine and prostacyclin respectively.

SPECT-single photon emission computed tomography for pulmonary perfusion or ventilation studies (paper I and III)

Regional lung blood flow was investigated using macro aggregates of albumin labelled with radioactive technetium $^{99m}\text{Tc}^{134}$. Regional ventilation was marked using Technegas, a dispersion of ultra fine carbon particles labelled with $^{99m}\text{Tc}^{25}$. All SPECT images were obtained with a three-headed gamma camera equipped with high resolution low-energy collimators. SPECT scans were performed in 90 projections during 360° rotation with an examination time of 20 minutes. A 128×128 matrix was used, giving a spatial resolution of 3.5 mm/pixel, for data acquisition and reconstruction.

SPECT data analysis:

3D images representing perfusion distribution were reconstructed from every acquisition performed. To be able to distinguish the effects of an intervention between two acquisitions a subtraction procedure was done to “eliminate” the disturbing activity from the former image. Corrections for attenuation were performed ²⁹.

In **paper I** perfusion distribution was analysed using rectangular volumes of interest (VOI)-width =18 mm and length = lung dimension in ventral–dorsal direction. Volumes were defined on the interface between the apical and mid and the mid and basal third of the right lung (Fig 2B). They were divided in two equal parts (ventral/dorsal) and their perfusion was expressed in percent of that in the entire VOI.





Figure 2. A) Design of study for SPECT analysis of pulmonary perfusion. Tracer administration and NO synthase inhibitor administration are indicated.

B) Frontal view of apical and basal sections of SPECT image planes. Rectangular volumes of interest (VOI) were defined on the interface of the apical and mid third (apical section), and the mid and basal third (basal section) of the right lung. The VOI has a width of 18 mm and a length corresponding to the depth of the right lung. The VOI was divided in two equal parts (ventral/dorsal) and activity in each part is presented as a percent of the entire VOI.


In **paper III** perfusion distribution was reconstructed in coronal sections from a 128x128 matrix, giving a spatial resolution of 3.5mm/pixel (Fig 3B). The average activity deposition from ventral to dorsal in both supine and prone position was calculated. Activity data were collected by dividing the area under activity distribution curve in 20 sections, each 5% of the ventro-dorsal length. In order to perform inter-individual comparisons the average activity distribution was normalized to the length of the lung from ventral to dorsal.

SPECT 1 after an intravenous injection of macro aggregates (50 MBq) illustrates perfusion under basal conditions. In paper I, perfusion distribution during NOS inhibition was obtained by subtracting SPECT 2 data from SPECT 3, which was performed after the second injection of macro aggregates (100 MBq). SPECT 2 was used to exclude any change in shape of basal activity. SPECT 1 and SPECT 2 were not significantly different, which made subtraction analysis possible (Fig. 2A) In paper III, SPECT I illustrates basal conditions and SPECT 2 conditions after intervention, i.e. inhalation of iloprost or infusion of diclofenac (Fig. 3A).

A Iloprost study



Diclofenac study



B




Figure 3. A) Protocol outline for the iloprost inhalation experiment (upper panel) and the diclofenac infusion experiment (lower panel). Blood samples for arterial bloodgases were taken every 10 min. Blood pressure and heart rate were registered every 5 min. For the ventilation SPECT procedure, see the upper panel. Instead of using an injection of 99mTc-labelled macro-aggregated human albumin (MAA), the volunteers inhaled a gas mix containing 99mTc-labelled ultra-fine carbonaceous particles for 1 min.

B) Lateral view with coronal sections of SPECT image planes.

Clinical investigation with shunt calculations during unilateral hypoxia (paper IV)

During thoracic surgery with one-lung ventilation unilateral alveolar hypoxia appears followed by a right to left shunt. The shunt fraction was investigated during pharmaceutical intervention. For sampling of mixed venous blood a thermo dilution catheter was placed in a pulmonary artery via the right internal jugular vein. Arterial blood gases were collected via a radial arterial line. Hemodynamic variables as continuous cardiac output, invasive systemic and pulmonary blood pressures, heart rate and gas exchange data were registered.

Shunt fraction was calculated using the formula proposed by Riley et al.¹³⁰. $Q_s/Q_t = (Cc'O_2 - CaO_2) / (Cc'O_2 - CvO_2)$. The $Cc'O_2$ is approximated with CAO_2 calculated according to the following formula $CAO_2 = 1.39 \times Hb + PAO_2 \times 0.23$ where $PAO_2 = FIO_2 (PB - PH_2O) - PACO_2 (FIO_2 + (1 - FIO_2) / RQ)$. (RQ = respiratory quotient. For a mixed diet assumed to be 0.8)

Study protocols

The study designs for the SPECT investigations are shown in (**paper I and III**) (Fig 2, Fig 3).

Pharmaceutical interventions

NO synthesis inhibition was achieved with N^G-monomethyl-L-arginine (L- NMMA) and the effect was verified by measurements of exhaled NO by chemiluminescence's according to American Thoracic Society guidelines⁹ (**Paper I**)

Prostaglandin synthesis inhibition was obtained with the non-selective cyclooxygenase inhibitor diclofenac¹⁵² (**Paper III**). The inhibition of prostacyclin synthesis was controlled with plasma analyses of 6-keto-prostaglandin1F α , a stable metabolite of prostacyclin¹⁰⁵.

Inhalation of a prostacyclin analogue Iloprost (Ilomedin®) was performed with a micro processor controlled ultrasonic nebulizer (Optineb®-ir). The systemic uptake was controlled with plasma analyses of 6-keto-prostaglandin1F α , a stable metabolite of prostacyclin.

Anesthesia**Patients**

All patients scheduled for lung surgery were premedicated with morphine intramuscularly (**paper I**) or diazepam 5-10 mg orally (**paper II**) and anesthetized with propofol 1-2 mg kg⁻¹, fentanyl 0.1 mg, glycopyrron 0.2 mg and midazolam 1-2 mg after application of a thoracic epidural catheter at level Th₅₋₆. A radial catheter was placed for continuous blood pressure measurements and arterial blood samples. Neuromuscular block was achieved with atracurium 0.5 mg kg⁻¹ followed by endobronchial intubation with a left-sided double lumen tube, size 37 CH for women and 39 CH for men. The correct position of the tube was confirmed by bronchoscopy, initially in supine and later in lateral decubitus position. Anaesthesia was maintained with propofol infusion 5-6 mg kg⁻¹ h⁻¹. An epidural infusion with bupivacain 5 mg /ml (**paper I**)/chirocaine 2.5 mg/ml (**paper II**) + sufentanil 1 microgram/ml of 4-6 ml/h was started after a test dose of 4 ml bupivacaine 5 mg/ml with adrenalin 5 microgram/ml was evaluated. Mean arterial pressure (MAP) was maintained within 30% of baseline values by administration of crystalloids and if necessary intermittent injections of 2-4 micrograms norepinephrine.

Mechanical ventilation was performed by using volume controlled ventilation with a Servo Ventilator (**paper I**) or a Draeger Julian Ventilator (**paper IV**) at FIO₂ of 0.6 or higher if deemed. Arte-

rial blood gases were sampled from a radial catheter and the ventilator was set to achieve normal PaCO₂ values. The I:E ratio was set to 1:2. In **paper I** there was no PEEP applied, in **paper IV** PEEP of 5 cm H₂O was applied.

Volunteers

There were no sedatives used in the studies (**paper I and III**). The volunteers were awake and spontaneously breathing.

Animals

After pre-medication with ketamine hydrochloride 500 mg intramuscularly anesthesia with pentobarbital sodium 25-30 mg kg⁻¹ was induced. When there was no reaction to painful stimuli, biopsies were taken from ventral and dorsal lung regions during spontaneous breathing, frozen within 1 minute in liquid nitrogen and stored in - 80°C. Then the heart and lungs were removed and the animals were exsanguinated.

Statistics

Data in the text and tables are presented as means ± SD or median and 25th and 75th quartiles. Statistical analysis was performed using SPSS for Windows. Statistical significance was tested according to Student's *t*-test (**paper I, III**), Wilcoxon rank sum test (**paper III**) or Mann-Whitney non parametric U-test (**paper IV**) for paired and unpaired data. Two way analysis of variance for repeated measures was used to compare related data (**paper I, paper III**). Linear regression analysis was used to investigate correlations between different factors (**paper IV**). Chi-square and Fisher's exact tests were used to analyse differences in number of subjects needing increased F_IO₂ in the different groups (**paper IV**). *P*-values < 0.05 were considered significant. In paper III, differences with 95% confidence intervals not intersecting with zero were considered significant.

Ethical considerations

All studies were approved by ethical committees and in **paper I and III** approvals by radiation protection committee were obtained. Written consent was obtained from all subjects in **paper I, III and IV**.

RESULTS

The results have been presented in detail in paper I-IV, and below follows a description of the findings more in general.

Differences in vasoreactivity between ventral and dorsal lung regions with reference to nitric oxide. (Paper I, II)

Humans: mRNA expression for eNOS was twice as high in dorsal compared to ventral lung tissue in humans. $P < 0.05$ (Fig. 4A).

The Ca^{2+} -dependent NOS activity was significantly higher (1.5 times) in dorsal compared to ventral human lung tissue (Fig. 4B).




Figure 4 A) Expression of mRNA for eNOS in ventral and dorsal lung tissue. Human lung eNOS mRNA levels are illustrated as relative units between the expression of eNOS mRNA and the housekeeping gene β -actin. Differences between the eNOS expression levels in dorsal and ventral parts of the lung were evaluated by Wilcoxon rank sum test for paired groups. (*= $P < 0.05$, $n = 13$).

B) NOS activity in ventral and dorsal lung tissue. Activity of nitric oxide synthase in human lung specimens obtained at surgery. The activity was determined in ventral (filled bars) and dorsal (open bars) specimens from the lower lobe in the presence and absence of 1.8 mM Ca^{2+} . (*= $P < 0.05$, $n = 21$).

Animals: The relaxing potency of acetylcholine and bradykinin, both endothelium dependent vasorelaxants acting via NO-release from vascular endothelium, was higher in isolated sub-maximally contracted porcine pulmonary arterial ring preparations from dorsal compared to ventral lung regions. Sodium nitroprusside, an endothelium independent NO-donor, was equally potent in relaxing dorsal and ventral isolated pulmonary arterial rings (Fig. 5).

The Ca^{2+} -dependent NOS activity was 1.4 times higher in dorsal compared to ventral porcine lung tissue. $P < 0.05$ (Fig. 6).





Figure 5. Porcine pulmonary artery. Cumulative dose-response curves for vasorelaxing agents on submaximal contractions to norepinephrine (10^{-6} M) in dorsally (open symbols) and ventrally (filled symbols) located porcine pulmonary arteries. There were significantly greater relaxation responses in dorsal than ventral pulmonary arteries to the endothelium-dependent vasodilators acetylcholine (10^{-7} – 10^{-5} M) ($P < 0.05$) (A) and bradykinin (10^{-10} – 10^{-7} M) ($P < 0.001$) (B). There were no significant differences in relaxation to the endothelium-independent vasodilator nitroprusside (10^{-7} – 10^{-5} M) (C). n = number of different animals.





Figure 6. Porcine lung. Nitric oxide synthase (NOS) activity determined by citrulline assay in ventral and dorsal lung tissue. The activity was determined in ventral (filled bars) and dorsal (open bars) biopsies from the lower parts of the lung in the presence and absence of 1.8 mM Ca^{2+} . * $P < 0.05$, $n = 18$.

NOS-inhibition, regional pulmonary perfusion and arterial oxygenation in vivo, healthy humans (Paper I)

Volunteers: In the supine position, NOS-inhibition with L-NMMA redistributed regional pulmonary perfusion from dorsal dependent lung regions to ventral pulmonary parts (Fig. 7). Dorsal perfusion decreased from 56 to 52% and ventral perfusion increased correspondingly from 44 to 48%. In the prone position, however, there was no redistribution of regional pulmonary blood flow detected after NOS-inhibition (Fig. 8).

There were no differences in arterial oxygenation after NOS-inhibition by L-NMMA in neither supine nor prone positions in healthy humans.

There was a well-tolerated 10% increase in systemic arterial pressure and 19% decrease in heart rate during NOS-inhibition with L-NMMA. There were no significant differences in heart rate or blood pressure during the NOS-blockade due to posture (Fig. 9).




Figure 7. SPECT image of pulmonary perfusion before and after NOS inhibition. SPECT acquisition in a healthy human volunteer before (a) and after (b) administration of the NO synthase inhibitor L-NMMA iv. A horizontal projection is shown with the ventral lung regions facing upwards and the dorsal downwards. The subject was placed in the supine position throughout the procedure, and the basal parts of the lungs are shown. R=right lung.




Figure 4. Regional pulmonary perfusion in supine and prone positions. Distribution of pulmonary blood flow is determined by SPECT in healthy human volunteers, studied at two different occasions in prone ($n=8$) and supine positions ($n=9$), respectively. The relative distribution was determined for the ventral (filled bars) and dorsal (open bars) regions of the lungs before and during intravenous infusion of the NO synthase inhibitor L-NMMA. At the first row, relative blood flow distribution in apical sections is shown and at the second row in basal sections. In the left column, data from supine positions are demonstrated, and in the right column, data from prone positions are shown. (Statistical significance in the figure is indicated for differences between control conditions and in the presence of L-NMMA for ventral and dorsal VOIs, respectively; $*p < 0.05$, $**p < 0.01$.)




Figure 9. Effects by L-NMMA on exhaled NO, blood pressure, and pulse rate (healthy human volunteers in prone and supine positions). Summary of effects of intravenous infusion of the NO synthase inhibitor L-NMMA on exhaled nitric oxide (FE_{NO}), arterial systolic (Syst) and diastolic (Diast) blood pressures, and heart rate (n = 17).

Differences in regional pulmonary perfusion and arterial oxygenation with reference to prostaglandins in healthy humans. (Paper III)

Decreased prostacyclin levels:

In healthy humans there were no significant differences in regional pulmonary perfusion in ventro-dorsal directions measured with SPECT after non-selective COX-inhibition (Fig.10). Neither arterial oxygenation, heart rate nor blood pressure differed between control and diclofenac groups.

Increased prostacyclin levels:

Arterial oxygenation: After inhalation of the synthetic prostacyclin analogue iloprost there was a decrease in arterial oxygenation which was of the same degree in both prone and supine positions; from 13.7 ± 1.4 kPa to 10.9 ± 2.1 kPa ($P < 0.01$) in supine and from 14.2 ± 0.5 kPa to 11.7 ± 1.7 kPa in prone position ($P < 0.01$, Fig 2 pekIII).

Changes in PaO₂ were normalized 30 minutes after termination of the iloprost inhalation (Fig.11).

Perfusion distribution: Iloprost inhalation induced an augmentation of blood flow in the dependent parts in both supine and prone position with a significant decrease in arterial oxygenation (Fig.12).

Ventilation distribution: After iloprost inhalation in the supine position, there was a significant change in the ventilation distribution from dependent to non-dependent lung regions.

Hemodynamic parameters: There was a transient increase in heart rate and decrease in arterial pressure during the iloprost-inhalation, normalized 8 min after termination of the inhalation. At the time when pulmonary perfusion distribution was measured by SPECT and the PaO₂ was diminished, heart rate and blood pressure were completely normalized. The concentration of 6-keto-prostaglandin F1 α was not altered at the time the radioactive tracer was injected and trapped in the pulmonary capillaries.




Figure 10. Blood flow as a function of % ventral-to-dorsal distance in supine and prone positions before and after infusion of 75 mg diclofenac. The plots demonstrate the normalized mean values \pm SD for the vertical lung sections, each 5% of the total distance along a ventral-to-dorsal axis, $n=10$. A) Perfusion distribution in the supine position, control (open circles) and after diclofenac infusion (filled circles). B) Perfusion distribution in the prone position, control (open circles) and after diclofenac infusion (filled circles). The edge effect (underestimation of radiotracer concentration at the lung periphery) causes blood flow per section to be underestimated at the extremes of the ventral-to-dorsal distance.




Figure 11. Effects by iloprost inhalation on PaO₂ in healthy volunteers in prone (open circles) and supine (filled circles) positions. PaO₂ decreased during inhalation of iloprost in both supine and prone positions ($P < 0.01$). There was no significant difference between the effect of iloprost in the supine and the prone position.




Figure 12. Blood flow as a function of % ventral-to-dorsal distance in supine and prone positions before and after inhalation of 20 μg iloprost. The top row: the plots demonstrate normalized mean values \pm SD for the vertical lung sections, each 5% of the total distance along a ventro-dorsal axis, $n = 9$. The first column shows the perfusion distribution in the supine position (A) control (open circles) and after iloprost inhalation (filled circles). The second column shows the perfusion distribution in the prone position (B) control (open circles) and after iloprost inhalation (filled circles). The edge effect (underestimation of radiotracer concentration at the lung periphery) causes blood flow per section to be underestimated at the extremes of the ventral-to-dorsal distance. The bottom row displays the differences section by section between the

regional perfusion distribution along the ventro-dorsal axis before and after iloprost inhalation in supine (C) and prone (D) positions. The lines show mean differences (filled squares) between blood flow with iloprost and control, low and high 95% confidence intervals (open squares), respectively. Confidence intervals that do not intersect with zero indicate a significant difference between drug and control. Perfusion increased in dependent regions and decreased in non-dependent regions in both the supine and the prone position. Note the different pattern in differences between drug and control in the supine as compared with the prone position.

Differences in pulmonary perfusion with reference to prostaglandins during regional hypoxia in vivo. (Paper IV)

In regional pulmonary hypoxia during one-lung ventilation (OLV) for thoracic surgery, the diclofenac treated group showed a significant reduction of the shunt fraction compared to the placebo group. After 15 minutes of OLV the shunt increased 3.1 times compared to base line measurements in the placebo group, while the increase was just 2.2 times in the diclofenac group ($P > 0.043$, Fig.13).

There were no differences between groups in patient characteristics or preoperative conditions (Table 4). During investigations there were no significant differences in perioperative bleeding, serum creatinine, respiratory or hemodynamic variables between the groups (Table 5, Table 6). Shunt fraction in the placebo group increased from 12 (10, 14) % (median (25th,75th percentiles)) during TLV to 39 (24, 44) % and 38 (31, 46) % after 15 and 30 minutes after OLV respectively. In the diclofenac group shunt fraction increased from 12 (12, 14) % at TLV to 28 (16, 36) % and 30 (18, 35) % after 15 and 30 minutes of OLV respectively. Shunt fraction was significantly improved in the diclofenac group compared with the placebo group after 15 minutes of OLV ($P = 0.043$), but not after 30 minutes of OLV ($P = 0.068$) (Fig.13). This lack of statistical significance might have been due to the smaller number of patients ($n = 20$) evaluated due to prior initiation of surgical vessel ligation at this time point. During left-sided surgery (LSS), shunt fraction was significantly improved at both 15 ($P = 0.020$) and 30 min ($P = 0.036$) of OLV (Fig.14 A). During right-sided surgery (RSS) reductions of shunt fractions due to diclofenac were not prominent and did not reach statistical significance (Fig.14 B).

Plasma concentrations of 6-keto-prostaglandin $F_{1\alpha}$ were [228 (164, 469 pg/ml)] in the placebo group and [73 (47, 94)] in the diclofenac group ($P = 0.003$) 60 minutes after start of the diclofenac infusion, i.e. at OLV 2.

In order to maintain SpO_2 above 90% FIO_2 had to be increased above 0.6 in 10 patients (4 RSS and 6 LSS) in the placebo group and in 5 patients (all RSS) in the diclofenac group ($P = 0.077$). Preoperative PO_2 and PCO_2 values were similar in patients requiring increased FIO_2 compared with those who did not. In the entire patient material PaO_2/FiO_2 ratios and $P(A-a)O_2$ differences were not changed after diclofenac treatment (Table 5). In patients subjected to left-sided lung surgery, however, $P(A-a)O_2$ values in the diclofenac treated patients at 15 minutes of OLV were significantly lower than in the placebo group ($P < 0.029$, Fig. 15).

Table 4. Patient demographics.

	placebo (n=16)	diclofenac (n=16)	P
Age (yr)	65 (28-76)	71 (36-81)	0.10
Females	9	12	
BMI (kg m ⁻²)	24.2 (20, 25)	26.7 (22.9, 28.3)	0.11
Hemoglobin (g l ⁻¹)	128 (120, 144)	137 (128, 143)	0.48
Albumin (g l ⁻¹)	38 (35, 40)	38 (37, 41)	0.35
Creatinine (g l ⁻¹)	72 (60, 93)	65 (58, 84)	0.30
PaO_2 kPa	10.4 (10.1, 10.8)	10.4 (8.9, 12.8)	0.96
$PaCO_2$ kPa	5.4 (5.1, 6.0)	5.1 (4.9, 5.6)	0.10
FEV_1 (liters s ⁻¹)	2.6 (1.9, 3.0)	2.1 (1.8, 2.7)	0.16
% of predicted FEV_1	84	85	
VC (liters)	2.9 (2.5, 4.1)	2.8 (2.6, 3.5)	0.8
% of predicted FVC	82	87	





Figure 13. Shunt fraction (%) in all patients, left and right thoracic surgery, pooled data for the placebo (unfilled) and diclofenac groups (filled boxes). Measurements were performed after induction of anesthesia (supine position), in lateral decubitus position during two-lung (TLV) and one-lung ventilation (OLV) and finally after restoration of TLV. Measurements were registered at 15 min intervals. The shunt was significantly larger in the placebo group at OLV2 ($P = 0.043$; $n = 16$). Data are presented as median, quartiles and 5th and 95th percentiles.

A



B




Figure 14 A) Shunt fraction (%) in patients subjected to left-sided thoracic surgery, placebo (unfilled) and diclofenac groups (filled boxes). Measurements were performed after induction of anesthesia (supine position) and in lateral decubitus position during two-lung (TLV) and one-lung ventilation (OLV) and finally after restoration of TLV. Measurements were registered at 15 min intervals. The shunt was significantly larger in the placebo group at OLV2 ($P = 0.020$) and at OLV3 ($P = 0.036$); $n = 8$). Data are presented as median, quartiles and 5th and 95th percentiles.

B) Shunt fraction (%) in patients, subjected to right-sided thoracic surgery, placebo (unfilled) and diclofenac groups (filled boxes). Measurements were performed after induction of anesthesia (supine position) and in lateral decubitus position during two-lung (TLV) and one-lung ventilation (OLV) and finally after restoration of TLV. Measurements were registered at 15 min intervals. The shunt was not significantly different between placebo and diclofenac ($P = 0.642$) at OLV2 and ($P = 0.667$) at OLV3; $n = 8$). Data are presented as median, quartiles and 5th and 95th percentiles.




Figure 15. $P(A-a)O_2$ during left-sided (A) and right-sided (B) thoracotomy in placebo (unfilled symbols) and diclofenac treated patients (filled symbols). Measurements were performed after induction of anaesthesia (supine position) and in lateral decubitus position during two lung (TLV) and one-lung ventilation (OLV) and finally after restoration of TLV. Measurements were registered at 15 min intervals. During left thoracotomy $P(A-a)O_2$ values were significantly different between placebo and diclofenac treated at OLV2 ($P = 0.024$), OLV3 ($P = 0.027$) and after restoration of TLV ($P = 0.032$; $n = 8$).

Table 5. Gas exchange data, pooled material

	PvO ₂	PaO ₂	PaCO ₂	P (A-a) O ₂	PaO ₂ /FIO ₂	% Shunt
TLV supine		p	p	p	p	p
placebo	5.8 (5.4, 6.0)	25.7 (19.4, 33.7)	5.4 (5.2, 5.6)	18.5 (13.0, 23.8)	49.5 (40.0, 61.2)	12 (10, 14)
diclofenac	5.8 (5.5, 6.1) ns	25.2 (18.8, 34.4) ns	5.0 (4.5, 5.4) ns	22.0 (13.0, 24.0) ns	46.5 (38.0, 61.2) ns	12 (10, 14) 0.850
lateral						
placebo	5.8 (5.4, 6.5)	24.4 (21.2, 30.7)	5.4 (5.2, 5.8)	19.0 (11.2, 24.5)	45.5 (39.5, 60.2)	12 (9, 14)
diclofenac	6.0 (5.9, 6.3) ns	26.3 (21.0, 34.5) ns	5.3 (5.0, 5.8) ns	17.0 (12.0, 19.0) ns	50.5 (43.0, 62.8) ns	13 (8, 15) 0.636
OLV 5 min						
placebo	5.5 (5.3, 5.8)	15.6 (10.2, 24.2)	5.6 (5.0, 5.9)	28.0 (24.2, 35.5)	30.0 (16.2, 41.5)	21 (16, 37)
diclofenac	5.9 (5.4, 6.3) ns	15.8 (12.5, 26.6) ns	5.2 (4.8, 5.4) ns	27.0 (18.2, 31.5) ns	29.0 (24.0, 48.2) ns	25 (14, 30) 0.854
15 min						
placebo	5.0 (4.8, 5.5)	9.0 (8.3, 10.0)	5.3 (4.9, 5.9)	39.0 (31.0, 51.0)	16.0 (12.0, 22.0)	39 (24, 44)
diclofenac	5.1 (4.9, 5.8) ns	9.3 (8.5, 22.8) ns	5.0 (4.8, 5.2) ns	32.0 (27.0, 41.0) ns	17.0 (15.0, 31.0) ns	28 (16, 36) 0.043
30 min						
placebo	5.0 (4.8, 5.5)	9.3 (8.6, 9.9)	5.4 (5.0, 5.9)	37.0 (34.0, 58.0)	15.0 (12.0, 17.0)	38 (31, 46)
diclofenac	5.1 (5.0, 6.1) ns	10.4 (8.4, 19.2) ns	5.1 (4.7, 5.2) ns	36.0 (31.0, 48.0) ns	16.0 (13.0, 35.0) ns	30 (18, 35) 0.068
after lig.						
placebo	5.0 (4.8, 5.5)	11.2 (9.8, 15.2)	5.4 (4.8, 5.7)	39.0 (30.8, 53.2)	19.0 (17.0, 22.8)	26 (21, 32)
diclofenac	5.5 (5.1, 5.8) ns	17.5 (10.7, 23.8) ns	4.9 (4.6, 5.1) ns	28.0 (21.8, 39.0) ns	28.5 (16.8, 42.8) ns	22 (14, 29) 0.198
TLV lateral						
placebo	5.5 (5.2, 6.0)	25.0 (20.8, 32.4)	5.3 (4.9, 5.7)	23 (14.0, 27.0)	48.0 (38.0, 58.0)	14 (8, 17)
diclofenac	5.6 (5.4, 6.1) ns	27.2 (24.2, 31.6) ns	5.2 (4.8, 5.5) ns	15.0 (9.2, 21.2) ns	51.0 (47.2, 64.2) ns	9 (7, 14) 0.092

Table 6. Hemodynamic data, pooled material

	HR		MAP		CVP		MPAP		CI		% Shunt	
TLV supine		p		p		p		p		p		p
placebo	72 (56, 75)		74 (61, 90)		15 (12, 17)		24 (18, 27)		2.2 (1.8, 2.4)		12 (10, 14)	
diclofenac	62 (56, 73)	ns	66 (60, 81)	ns	16 (12, 18)	ns	24 (19, 26)	ns	2.2 (1.4, 3.2)	ns	12 (10, 14)	0.850
lateral												
placebo	68 (55, 74)		72 (64, 89)		16 (13, 18)		23 (21, 27)		2.3 (2.0, 2.6)		12 (9, 14)	
diclofenac	67 (59, 75)	ns	72 (68, 92)	ns	16 (13, 20)	ns	26 (19, 31)	ns	2.6 (2.1, 3.0)	ns	13 (8, 15)	0.636
OLV 5 min												
placebo	72 (68, 81)		74 (65, 90)		14 (13, 17)		24 (23, 27)		2.4 (2.0, 2.8)		21 (16, 37)	
diclofenac	73 (64, 78)	ns	77 (72, 88)	ns	15 (12, 19)	ns	24 (20, 30)	ns	2.5 (2.1, 2.8)	ns	25 (14, 30)	0.854
15 min												
placebo	73 (66, 80)		70 (62, 78)		17 (14, 18)		26 (23, 27)		2.4 (2.1, 2.6)		39 (24, 44)	
diclofenac	73 (62, 75)	ns	70 (64, 83)	ns	15 (12, 16)	ns	24 (22, 29)	ns	2.6 (2.3, 2.8)	ns	28 (16, 36)	0.043
30 min												
placebo	76 (71, 86)		67 (66, 90)		16 (14, 19)		25 (24, 29)		2.7 (2.1, 3.1)		38 (31, 46)	
diclofenac	70 (65, 82)	ns	82 (64, 95)	ns	15 (13, 16)	ns	25 (21, 29)	ns	2.8 (2.3, 3.1)	ns	30 (18, 35)	0.068
after lig.												
placebo	71 (64, 82)		72 (67, 81)		16 (13, 17)		26 (23, 28)		2.5 (2.2, 2.8)		26 (21, 32)	
diclofenac	69 (61, 82)	ns	86 (78, 92)	ns	15 (13, 16)	ns	26 (21, 30)	ns	2.5 (2.1, 2.9)	ns	22 (14, 29)	0.198
TLV lateral												
placebo	70 (60, 75)		72 (70, 88)		15 (11, 18)		26 (21, 29)		2.6 (2.0, 2.8)		14 (8, 17)	
diclofenac	67 (62, 82)	ns	78 (65, 86)	ns	14 (11, 17)	ns	24 (22, 29)	ns	2.4 (2.1, 2.9)	ns	9 (7, 14)	0.092

DISCUSSION

The highlights of this thesis are that endogenous NO synthesis is involved in regional regulation of pulmonary vascular tone and that NO production is higher in dorsal compared with ventral lung regions in humans. SPECT images in volunteers, before and after NOS inhibition, verify the functional importance of these findings.

The higher degree of NO production in the dorsal parts of the lungs provide the final link in searching for an answer to questions raised by a study 1986, where Beck and Rehder ¹⁴ demonstrated higher vascular conductance in dorsocaudal compared to ventrocephaled regions in isolated dog lungs. The results contribute to better understanding of the more uniform perfusion distribution ^{65, 80, 104, 147, 155} and V/Q ratios ^{7, 99, 129} with improvement in oxygenation demonstrated when patients with ALI and ARDS are turned into prone position ^{24, 39, 100}.

Are there differences in regional pulmonary vasoreactivity to nitric oxide?

An important determinant for regional distribution of pulmonary blood flow has, during the recent decades, been suggested to be the fractal anatomy of the vascular tree ^{49, 52, 55, 66, 129}. However, vascular trees are not passive structures. Regional differences in smooth muscle vascular tone may modify the influence of an “intrinsic structure”, as we have demonstrated in these series. First, we have shown differences in vasoreactivity between isolated porcine arterial rings from dorsal and ventral pulmonary arteries to the endothelial-dependent vasorelaxants, acetylcholine and bradykinin, acting via nitric oxide release (**paper II**). Second, the mRNA expression of eNOS is higher in dorsal compared with ventral human lung tissue. Ca²⁺-dependent NOS-activity, as measured by citrulline assay is higher in dorsal lung regions in two different species, humans and pigs. Finally, NOS-inhibition by L-NMMA *in vivo* redirected blood from dorsal to ventral lung regions in the supine position (**paper I**). **In paper II**, we could also define the endothelium as the site of interest for the differences in vasoreactivity in the pulmonary arteries, by investigating the effect of an endothelium-independent NO-donor, sodium nitroprusside. Sodium nitroprusside, acting directly on the smooth muscle cell, showed no differences in vasorelaxing potency between dorsal and ventral porcine arterial rings, in contrast to the endothelium-dependent vasodilator acetylcholine.

Our findings are consistent with earlier *in vitro* studies. Beck and Rehder demonstrated in 1986 a higher vascular conductance in dorsocaudal than in ventrocephalad regions of isolated perfused dog lungs ¹⁴. Later, Pelletier et al. showed a more pronounced endothelium-dependent vascular relaxation in dorsal compared to ventral isolated equine pulmonary arterial rings to a number of substances acting via the cGMP / NO pathway ¹¹¹.

Whether the increased NOS activity in dorsal lung regions, found in our study, is a primary or secondary phenomenon cannot be fully answered by this study. NO production *in vivo* is regulated by different factors. Shear stress caused by high blood flow may result in enhanced NO synthesis in dorsal lung regions ¹²⁰. This might indicate that the observed higher Ca²⁺-dependent NOS activity described in this study is a secondary phenomenon and not the cause of higher blood flow in dorsal regions in the supine position. NOS activity was analyzed *in vitro* under standardized conditions, for example, equal amounts of enzyme substrate, L-arginine, indicating that constitutional enzyme activity was higher in dorsal lung regions. The NOS activity analysed in our study was not influenced by shear stress because the analysis was made *in vitro*, not in blood vessels *in vivo*. Ca²⁺-independent, inducible NOS activity did not differ between ventral and dorsal tissue samples. Furthermore, expression of mRNA for eNOS was higher in dorsal regions. Taken together, our

results strongly suggest a difference in eNOS mRNA expression and Ca²⁺-dependent NOS activity under basal conditions, leading to differences in vasoreactivity in dorsal and ventral lung regions. To summarise, the findings in paper I and II add evidence to a regulatory role for nitric oxide in regulation of regional pulmonary blood flow distribution.

Can differences in regional pulmonary vasoreactivity play a role in regional lung blood flow distribution with reference to posture?

A dominant dorsal lung perfusion in the supine position^{8, 77} and more uniform perfusion in the prone position has been shown in previous studies in humans and animals during spontaneous ventilation^{65, 101, 104, 155}. These earlier findings were obtained with the use of various techniques such as radiospinometry¹³ and SPECT in humans¹⁰⁸ and microspheres in animals^{65, 155}. The agreement between different species using a variety of techniques indicate a true description of physiologic conditions, which is further strengthened in this study. It should be kept in mind that the present SPECT method does not measure perfusion per se but the image produced by radioactive microspheres trapped in capillaries. Also, it is important to keep in mind the confounding effects by the compressible nature of lung parenchyma when evaluating perfusion redistribution caused by changes in posture. Normalisation for perfusion / alveolus or density instead of unit volume must be considered^{118, 123}. The tracer technique is, on the other hand, well established^{13, 92} and allows for relative comparisons, as conditions are stable between the acquisitions. NOS inhibition by L-NMMA in the supine position redirected blood from dorsal to ventral lung regions (Fig. 7, Fig. 8). Most probably this is caused by a relatively larger change in the vascular tone of dorsal pulmonary vessels as compared with ventral vessels while supine. However, it is surprising that NOS inhibition while prone did not result in a parallel redirection of pulmonary blood flow. Hence, body position may affect the response to L-NMMA. It is not likely that this is due to technical factors concerned with the SPECT technique or the infusion of the NOS inhibitor.

This observation may invoke the assumption that the mechanical change, supine to prone, causes a different stretching of the pulmonary vasculature that changes the response to L-NMMA. Increased exhalation of NO during ventilation with positive end expiratory pressure in rabbits has been suggested to be caused by a stretch-dependent regulation of pulmonary NO formation in animals^{1, 116}. The greater compression of dependent lung regions in supine^{4, 124} results in regional hypoxia⁷ which may induce HPV in dorsal regions. The higher NO production in dorsocaudal regions, found in this study, will attenuate HPV⁴⁶. Hence, inhibition of NO production by L-NMMA would enhance HPV leading to redistribution of pulmonary blood flow. A weaker regional HPV due to less tissue compression in prone position may explain the lack of effect by L-NMMA in prone posture. However, the difference in response to NOS inhibition between supine and prone position could not be fully explained in this study, and further investigations need to confirm and clarify this point.

The increased vascular conductance in dorsal lung regions, demonstrated by Beck and Rehder, could be explained by anatomical differences such as number of vessels and branching differences. Fractal vascular trees and perfusion heterogeneity in iso-gravitational planes suggest an anatomic structural basis for regulation of regional pulmonary blood flow^{49, 55, 66, 129}. The Seattle group⁷ demonstrated in 2004, by in vitro microsphere technique in anesthetized, mechanically ventilated pigs, that pulmonary structure was responsible for around 65% of total blood flow heterogeneity and around 75% of total ventilation heterogeneity. There was a posture-mediated relatively small redistribution of blood flow primarily oriented along the ventrodorsal axis, with increased blood flow to the dependent regions, more pronounced in the supine position. Hence, gravity contributes to regulation of regional pulmonary perfusion, but has to be considered as a secondary determinant^{51, 53}.

However, these observations do not exclude differences in regional pulmonary vasoreactivity to nitric oxide, found in this thesis, as an important contributor to the increased vascular conductance in dorsal lung regions and more uniform pulmonary perfusion distribution seen in the prone position.

Are there differences in regional pulmonary vasoreactivity to prostacyclin?

Regional pulmonary vasoregulatory differences could include other signal systems than those mediated by NO / guanylylcyclase / cGMP pathway (**paper I, II**). The prostaglandin system, for instance, involves substances acting via the adenylyl cyclase / cAMP pathway. Inhalation of the synthetic prostacyclin analogue iloprost has been shown to have selective pulmonary vasorelaxing effects^{12, 105, 107}. In this thesis, we could not confirm any regional differences in effects on regional pulmonary basal vascular tone to an exogenous prostacyclin analogue. Iloprost inhalation in both supine and prone positions increased perfusion in dependent lung regions, i.e., enhanced the effect of gravity (Fig.12). Non-selective COX-inhibition did not redistribute blood flow in either prone or supine position, which further supported the suggestion that the eicosanoid system is not involved in regulation of regional pulmonary perfusion in normal lungs (Fig.10). However, the limited number of observations cannot exclude an action by endogenous eicosanoids.

The observed effects in this study might be explained by an uneven gravity dependent drug distribution. The iloprost particle size used in the present study, should guarantee a drug deposition in peripheral airways^{135, 150}. Ventilation distribution was also studied in a subset of the volunteers in supine position. Iloprost, which is known to have bronchorelaxant effects¹⁴³, redistributed ventilation towards ventral, that is, non-dependent lung regions. This argues against that an uneven, preferentially dependent distribution of inhaled iloprost would explain the perfusion redistribution towards dependent lung regions in both supine and prone positions.

Surprisingly, iloprost inhalation in these healthy volunteers caused a decrease in arterial oxygenation in both the supine and prone position (Fig.11). The PBF redistribution towards dependent regions regardless of body position, and the gas redistribution in opposite direction in supine position, contributed to increased V/Q mismatch with impaired arterial oxygenation. Other possible mechanisms behind the changed oxygenation might be altered cardiac output by systemic drug effects. However, the administration method and dose of iloprost presently used has been shown to selectively dilate pulmonary vasculature^{105, 107}. Although heart rate and blood pressure increased during the iloprost inhalation, they were completely normalized when pulmonary perfusion distribution was measured by SPECT and at the same time PaO₂ was diminished. Furthermore, the fact that the concentration of 6-ketoprostaglandinF1 α was not altered at the time the radioactive tracer was injected and trapped in the pulmonary capillaries strongly indicates that the effect by iloprost on pulmonary perfusion distribution was mediated via local receptors in the lungs and not indirectly via systemic effects.

Vasoactive drugs, hypoxic pulmonary vasoconstriction and regional pulmonary perfusion.

The effects of iloprost inhalation in healthy humans are not consistent with the findings in several clinical studies where patients with ALI and ARDS have been treated with inhalations of prostacyclin or its analogues and have shown improved oxygenation^{35, 153}. In experimental lung injury models enhanced pulmonary vascular resistance has been demonstrated due to either damaged endothelial function or hypoxic vasoconstriction or a combination of the two³³, which might explain the favourable effects of prostacyclin treatment in severe lung disease. These observations confirm that underlying pathophysiology, the clinical conditions or the presence of positive pressure ventilation with concomitant effects on pre-existing vascular tone are of crucial importance for the effects of vasoactive substances⁵⁸.

In the present studies, COX-inhibition on healthy humans (**paper III**) did not influence regional blood flow distribution, while in the hypoxic situation (**paper IV**) during one lung ventilation for thoracic surgery, there was a marked reduction of shunt fraction due to redistributed blood flow after administration of a non-selective COX-inhibitor during left-sided thoracic surgery. Other factors like anesthetic agents^{15, 16, 20, 78, 79, 89, 109, 126}, cardiac output⁴², hypercapnia^{38, 43} and pulmonary blood flow³⁷ known to interact with HPV and shunt fraction were similar in the placebo and diclofenac groups. These factors were therefore less likely to be responsible for the observed differences between the groups.

It is well documented in animal and human studies that HPV is modulated by endothelial derived vasoactive substances^{46, 138}. When lung pathology and hypoxia is at hand, the effect of COX-inhibition might be different compared to normal physiological conditions^{35, 58, 69, 105, 153, 165}. During one-lung ventilation the low alveolar oxygen tension activates HPV in the non-ventilated lung with a redistribution of 40-50 % of the blood flow to the ventilated lung¹⁸. Our findings in humans are consistent with many in vitro and in vivo animal studies, showing decreased shunt fraction and improved arterial oxygenation after administration of non-selective COX-inhibitors when regional hypoxia is induced^{6, 59, 138}.

Interestingly, there was a posture related difference in the response to prostaglandin-inhibition during one lung ventilation in the lateral decubitus position. Alterations of lung perfusion are also known to be influenced by changes in body position^{7, 30, 104, 119, 129}. However, the smaller effect on the shunt fraction by COX inhibition in patients with right-sided surgery was interesting and difficult to explain. In the lateral decubitus position the dependent lung has a reduced lung volume due to anesthesia, muscular paralysis and compression by the mediastinal and abdominal contents¹⁰³, all of which contribute to atelectasis¹⁴⁵ and a decrease in compliance⁸². Hence, both pulmonary perfusion and ventilation will be compromised, more marked when the smaller left lung is dependent³⁰. This leads to a lower regional P_{O_2} and therefore a higher grade of HPV in the ventilated lung when the left lung is dependent³⁰, which might counteract the blood flow redistribution from the non-ventilated lung. In addition, HPV is more effective in diverting blood flow and reducing hypoxemia when the hypoxic region is a small fraction of the total lung⁸⁸. Thus, it is possible that the effect of COX inhibition on blood flow redistribution due to HPV is more effective when the larger right lung is dependent. Hence, body position cannot be ruled out as contributory factor to the observed difference in effect by COX-inhibition between left and right thoracotomy.

What are the clinical implications of the findings in this thesis?

It is of great importance to understand the causative mechanisms to impaired gas exchange in patients with lung pathology to be able to find new treatment strategies. There exists an extensive amount of research concerning the many passive factors determining PBF distribution like gravity and posture^{119, 125, 162}, vascular structure^{49, 52, 55, 66} and lung mechanics^{103, 114}. Some of these factors can be used in clinic practice by changing body posture and by optimizing ventilation characteristics.

In this thesis we have investigated the role of the vasoactive endothelial-derived factors, NO and prostacyclin, in regulation of regional PBF during normal and hypoxic conditions. The findings in the present thesis, that there are differences in vasoreactivity between dorsal and ventral pulmonary regions due to higher endothelial production of NO in dorsal pulmonary arteries might have clinical implications. Selective inhibition of eNOS activity in order to redistribute PBF from the dependent dorsal regions in the supine position may become a valuable tool in the treatment of patients with ALI or ARDS. The blood flow redistribution may lead to a more homogeneous ventral-to-dorsal perfusion distribution which in turn may improve arterial oxygenation due to optimised ventilation/perfusion matching.

The findings in paper IV that the use of a non-selective COX-inhibitor during one-lung ventilation decreases shunt during left-sided thoracic surgery has interesting clinical implications. First, the patients subjected to thoracic surgery are often elderly with inherent lung diseases and thus might benefit from preoperative COX-inhibition to reduce the risks for severe perioperative hypoxia during one-lung ventilation. Especially in minimally invasive thoracic procedures, requiring a well-collapsed lung, where CPAP to the non-ventilated lung is inapplicable, COX-inhibition may be advantageous^{22, 26}. Second, non-selective COX-inhibition may offer an easy way to minimize the exposure to high $F_{I}O_2$, minimizing absorption atelectasis⁴¹ and decreasing the risk of oxygen toxicity and inflammatory activation in the ventilated lung^{74, 83, 122}.

CONCLUSIONS

Based on the results in this thesis it was concluded that:

- expression of mRNA for endothelial nitric oxide synthase (eNOS) in humans is higher in dorsal than ventral lung regions **(I)**.
- Ca²⁺-dependent NOS activity is higher in dorsal compared with ventral human lung regions **(I)**.
- in pigs Ca²⁺-dependent NOS activity is higher in dorsal than in ventral lung regions **(II)**.
- relaxation of porcine pulmonary arteries by endothelium dependent vasoactive mediators such as acetylcholine and bradykinin is more potent in dorsal than in ventral arteries **(II)**.
- the endothelium independent NO donor sodium nitroprusside relaxes, in pigs, ventral and dorsal pulmonary arteries equally **(II)**.
- in supine volunteers, pulmonary blood flow is redirected from dorsal to ventral lung regions during NOS inhibition **(I)**.
- iloprost inhalation redistributes pulmonary blood flow to dependent lung regions regardless of posture while ventilation is redirected towards non-dependent lung regions in supine position leading to decreased arterial oxygen tension in healthy humans **(III)**.
- non-selective inhibition of cyclooxygenase (COX) by diclofenac does not affect pulmonary perfusion distribution in healthy humans **(III)**
- non-selective inhibition of cyclooxygenase (COX) by diclofenac reduces shunt fraction during one-lung ventilation for left sided thoracic surgery, accompanied with improved gas exchange, showed by a decrease in alveolo – arterial oxygen tension difference. **(IV)**.

GENERAL CONCLUSIONS

Based on the results in this thesis it was concluded that there exist differences in pulmonary vasoreactivity between ventral and dorsal lung regions for the endothelial derived mediator nitric oxide, at different levels such as gene transcription and enzyme activity, adding new knowledge contributing to logical explanations to variations in gas exchange between supine and prone positions.

The eicosanoid system is involved in regional perfusion distribution during regional hypoxia.

This knowledge may improve treatment strategies for patients with acute lung injury and acute respiratory distress syndrome and for patients subjected to one-lung ventilation during thoracic surgery.

ACKNOWLEDGEMENTS

I wish to express my sincere gratitude to all involved in completion of this thesis and especially to:

Claes Wiklund, my tutor, for introducing me to the field of science in the experimental laboratory as well as in all the practical details needed for reaching the goal, for never failing enthusiasm and optimism, even during dark moments, for patience during all hours shared in front of the computer fighting statistics, diagrams and comments from referees and thank you for all chocolate bars while training my scientific argumentation.

Sten Lindahl, my first tutor, for holding on to a true scientific atmosphere at the Karolinska University Hospital in spite of a non-scientific political era. For engaging and believing in me as a PhD student and for providing me with excellent research conditions. For great knowledge and brilliant scientific intuition and for always being available in spite of a full calendar. Without your enthusiastic support this thesis would never have been completed, and thank you for all good discussions and laughs beside the scientific work.

All co-authors for constructive scientific discussions, especially **Alejandro Sanchez-Crespo** for all your professional work with the nuclearmedical part of this thesis and **Peter Wiklund**, co-supervisor, for generous support and valuable discussions.

Jan Hultman, Dan Lindblom and Ulf Kjellman, actual and former heads of the department, for giving opportunities for and defending the importance of scientific work at the Clinic for Cardiot-horacic Surgery and Anesthesia.

Anette Ebberyd, biomedical research manager, for excellent technical and logistic support with all the practical work, for planning and making things work during long days in the experimental laboratory or in the operating theatre. Without your never ending helpful, constructive and professional support these studies would never have been accomplished. Thanks also to **Gunilla Barr** and **Mikael Antonsson** for invaluable support in the operating theatre, to **Nasrine Bavand-Chobut** for professional help in the laboratory and all the kind and helpful staff at the section for Nuclear Medicin.

All my colleagues and co-workers at the Clinic for Thoracic surgery and Anesthesia for kind support and encouragement during all these years of research. Professor **Jan van der Linden**, associate professor **Anders Öwall** and doctor **Lars Gunnarsson** for valuable scientific advices. Thank you all for keeping me on track.

Ulric Sartipy, cardiac surgeon, for extraordinary kindness and always ready to help with statistics and advice concerning all perspectives of research and thesis writing.

My admirable parents, **Alfonas**, who is no longer with us, and **Irène** for your never failing optimism and believe in life, for raising me with love always believing in me and inspiring me to go in for a medical career.

My sister **Elisabet** and my brother **Alf** and their families for always supporting and encouraging me.

Svante, my love and best friend, for sharing my every day life.

Malin and Felix, my beloved children, for all your support and love. You are my pride - you are my life!

REFERENCES

1. Adding LC, Bannenberg GL, Gustafsson LE. Gadolinium chloride inhibition of pulmonary nitric oxide production and effects on pulmonary circulation in the rabbit. *Pharmacol Toxicol* 1998; 83:8-15
2. Akata T. Cellular and molecular mechanisms regulating vascular tone. Part1: basic mechanisms controlling cytosolic Ca²⁺ concentration and the Ca²⁺-dependent regulation of vascular tone. *J Anesth* 2007; 21: 220-231
3. Akata T. Cellular and molecular mechanisms regulating vascular tone. Part 2: regulatory mechanisms modulating Ca²⁺ sensitivity in vascular smooth muscle cells. *J Anesth* 2007; 21: 232-242
4. Albert RK, Hubmayr RD. The prone position eliminates compression of the lungs by the heart. *Am J Respir Crit Care Med* 2000; 161: 1660-1665
5. Albert RK, Leasa D, Sanderson M, Robertson HT, Hlastala MP. The prone position improves arterial oxygenation and reduces shunt in oleic-acid-induced acute lung injury. *Am Rev Respir Dis* 1987; 135: 628-633
6. Alexander JM, Nyby MD, Jasberg KA. Prostaglandin synthesis inhibition restores hypoxic pulmonary vasoconstriction. *J Appl Physiol* 1977; 42 (6):903-8.
7. Altemeier WA, McKinney S, Krueger M, Glenny R.W. Effect of posture on regional gas exchange in pigs. *J Appl Physiol* 2004; 97: 2104-2111
8. Amis TC, Jones HA, Hughes JMB. Effect of posture on inter-regional distribution of pulmonary perfusion and V_A/Q ratios in man. *Respir Physiol* 1984; 56: 169-182
9. Anonymous: Recommendations for standardized procedures for the on-line and off-line measurements of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children. *Am J Respir Crit Care Med* 1999; 160: 2104-2117
10. Archer SL, Tolins JP, Raji L, Weir EK. Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium derived relaxing factor. *Biochem Biophys Res Commun* 1989; 164:1198-1205
11. Barnes JP, Liu SH. Regulation of pulmonary vascular tone. *Pharmacological reviews* 1995; 47: 87-131
12. Baker SE, Hockman RH. Inhaled iloprost in pulmonary arterial hypertension. *The Annals of Pharmacotherapy* 2005; 39; 7: 1265-1274
13. Beck CK. Regional trapping of microspheres in the lung compares well with regional blood flow. *Respiration* 1987; 63: 883-889

14. Beck CK, Rehder K. Differences in regional vascular conductances in isolated dog lungs. *J Appl Physiol* 1986; 61(2): 530-538
15. Beck DH, Doepfmer UR, Sinemus C, Bloch A, Schenk MR, Kox WJ. Effects of sevoflurane and propofol on pulmonary shunt fraction during one-lung ventilation for thoracic surgery. *BJA* 2001; 86 (1):38-43.
16. Benumof JL, Augustine SD, Gibbons JA. Halothane and isoflurane only slightly impair arterial oxygenation during one-lung ventilation in patients undergoing thoracotomy. *Anesthesiology* 1987; 67:910-5
17. Benumof JL. Choice of anesthetic drugs and techniques. In: Benumof JL, ed. *Anesthesia for thoracic surgery*. 2nd ed. WB Saunders Company, 1995:300-329
18. Benumof JL. One – lung ventilation and hypoxic pulmonary vasoconstriction: Implications for anaesthetic management. *Anesth Analg* 1985; 64:821-33
19. Bernhard GR, Artigas A, Brigham KL. The American-European consensus conference on ARDS. *Am J Respir Crit Care Med* 1994; 149: 818-24
20. Bjertnaes LJ. Hypoxia-induced vasoconstriction in isolated perfused lungs exposed to injectable or inhalational anaesthetics. *Acta Anaesth Scand* 1977; 21:133-47
21. Brashers VL, Peach MJ, Rose CE Jr. Augmentation of the hypoxic pulmonary vasoconstriction in the isolated rat lung by in vitro antagonists of endothelium-dependent relaxation. *J Clin Invest* 1988; 82: 1495-1502
22. Brown RD, Cafer RED, Roberson OV, Wilcox BR, Murray GF. Improved oxygenation during thoracotomy with selective PEEP to the dependent lung. *Anesth Analg* 1977; 56:26-31
23. Brudin LH, Rhodes CG, Valind SO, Jones B, Hughes JMB. Relationship between regional ventilation and vascular and extravascular volume in supine humans. *J Appl Physiol* 1994; 76: 1195-1204
24. Bryan A.C. Comments of a devils advocate. *Am J Respir Dis* 1974; 110: 143-144
25. Burch WM, Sullivan PJ, Mc Laren CJ. Technegas-a new ventilation agent for lung scanning. *Nucl Med Commun* 1986; 7: 865-871
26. Capan LM, Turndorf H, Chandrakant P, Ramanathan S, Acipanura A, Shalon J. Optimization of arterial oxygenation during one-lung anesthesia. *Anesth Analg* 1980; 59:847-51
27. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. *Prostaglandins Other Lipid Mediat* 2007; 82: 85-94
28. Casado-Flores J, Martinez de Azagra A, Ruiz-Lopez MJ, Ruiz M, Serrano A. Pediatric ARDS: effect of supine-prone postural changes on oxygenation. *Intensive Care Med* 2002; 28: 1792–1796.

29. Chang L-T. A method for attenuation correction in radionuclide computed tomography. *IEEE Trans Nucl Sci* 1978; 25: 638–643.
30. Chang H, Lai-Fook SJ, Domino KB, Schimmel C, Hildebrandt J, Robertson HT, Glennt RW, Hlastala MP. Spatial distribution of ventilation and perfusion in anesthetized dogs in lateral postures. *J Appl Physiol* 2002; 92: 745-762
31. Chen L, Williams JJ, Alexander CM, Roy RJ, Marshall C. The effects of pleural pressure on the hypoxic pulmonary vasoconstrictor response in closed chest dogs. *Anesth Analg* 1988; 67: 673-9
32. Cassoly R, Gibson QH. Conformation, co-operativity and ligand binding in human haemoglobin. *J Mol Biol* 1975; 91: 301-313
33. Dembinski R, Max M, Lòpez F, Kuhlen R, Kurth R, Rossaint R. Effect of inhaled Prostacyclin in combination with Almitrine on ventilation-perfusion distributions in experimental lung injury. *Anesthesiology* 2001; 94: 461-467
34. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signalling pathway. *Biochim Biophys Acta* 1999; 5; 1411(2-3):334-50
35. Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI₂) in acute respiratory distress syndrome: Impact of primary (pulmonary injury) and secondary (extra pulmonary injury) disease on gas exchange response. *Crit Care Med* 2001; 29: 57-62
36. Domino KB, Chen L, Alexander CM, Williams JJ, Marshall C, Marshall BE. Time course and responses of sustained hypoxic pulmonary vasoconstriction in the dog. *Anesthesiology* 1984; 60: 562-566
37. Domino KB, Westein L, Tran T, Hlastala MP. Increased pulmonary perfusion worsens ventilation-perfusion mismatch. *Anesthesiology* 1993; 79: 817-21
38. Dorrington KL, Talbot NP. Human pulmonary vascular response to hypoxia and hypercapnia. *Eur J Physiol* 2004; 449: 1-15
39. Douglas WW, Rehder K, Beynen FM, Sessler AD, Marsh HM. Improved oxygenation in patients with acute respiratory failure: the prone position. *Am Rev Respir Dis* 1977; 115(4): 559-566
40. Dupuis J, Langleben D, Stewart DJ. Pulmonary hypertension. Harwood Academic Publishers. In Rubanyi GM (ed): *Pathophysiology and clinical applications of nitric oxide* 1999.
41. Edmark L, Kostova-Aherdan K, Enlund M, Hedenstierna G. Optimal oxygen concentration during induction of general anesthesia. *Anesthesiology* 2003; 98: 28-33
42. Eisenkraft JB. Effects of anesthetics on the pulmonary circulation. *Br J Anaesth* 1990; 65:63-78
43. Emery CJ, Sloan PJM, Mohammed FH, Bare GR. The action of hypercapnia during hypoxia on pulmonary vessels. *Bull Europ Physiopath Resp* 1977; 13: 763-776

44. Ferrario L, Amin HM, Sugimori K. Site of action of endogenous nitric oxide on pulmonary vasculature in rats. *Pflugers Arch* 1996; 432: 523
45. Frangos JA, Eskin SG, McIntire LV, Ives CL. Flow effects on prostacyclin production by cultured endothelial cells. *Science* 1985; 227: 1477
46. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. *Circulation* 1991; 83(6): 2038-2047
47. Furchgott RF, Zadaewski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980; 288: 373-376
48. Gal TJ. Anatomy and physiology of the respiratory system and the pulmonary circulation. Kaplan JA, Slinger PD, eds. *Thoracic anesthesia*. 3rd edition, Philadelphia, Elsevier Science 2003: 57-70
49. Galvin I, Drummond GB, Nirmalan M. Distribution of blood flow and ventilation in the lung: Gravity is not the only factor. *Br J Anaesth* 2007; 98: 420-428
50. Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V, Malacrida R, Di Giulio P, Fumagalli R, Pelosi P, Brazzi L, Latini R. Effect of prone positioning on the survival of patients with acute respiratory failure. *N Engl J Med* 2001; 345: 568-573
51. Glenny RW, Bernard SL, Robertsson HT, Hlastala MP. Gravity is an important but secondary determinant of regional blood flow in upright primates. *J Appl Physiol* 1999; 86: 623-632
52. Glenny RW, Bernard SL, Robertsson HT. Pulmonary blood flow remains fractal down to the level of gas exchange. *J Appl Physiol* 2000; 89: 742-748
53. Glenny RW, Lamm WJ, Albert RK, Robertson HT. Gravity is a minor determinant of pulmonary blood flow distribution. *J Appl Physiol* 1991; 71: 620-629
54. Glenny RW, Lamm WJ, Bernard SL, An D, Chornuk M, Pool SL, Wagner WW Jr, Hlastala MP, Robertson HT. Selectid contribution: Redistribution of pulmonary perfusion during weightlessness and increased gravity. *J Appl Physiol* 2000; 89: 1239-1248
55. Glenny RW, Robertson TH. Fractal properties of pulmonary blood flow: characterization of spatial heterogeneity. *J Appl Physiol* 1990; 532-545
56. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. *Annu Rev Physiol* 1995; 57: 737-769
57. Guerin C, Gaillard S, Lemasson S, Ayzac L, Girard R, Beuret P, Palmier B, Le QV, Sirodot M, Rosselli S, Cadierque V, Sainty JM, Barbe P, Combourieu E, Debatty D, Rouffineau J, Ezingard E, Millet O, Guelon D, Rodriguez L, Martin O, Renault A, Sibille JP, Kaidomar M. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. *JAMA* 2004; 17:292(19): 2379-2387

58. Gust R, McCarthy TJ, Kozlowski J, Stephenson AH, Schuster DP. Response to inhaled nitric oxide in acute lung injury depends on distribution of pulmonary blood flow prior to its administration. *Am J Respir Crit Care Med* 1999; 159: 563-570
59. Hales CA, Rouse ET, Slate JL. Influence of aspirin and indomethacin on variability of alveolar hypoxic vasoconstriction. *J Appl Physiol* 1978;45:33-9
60. Hamasaki Y, Tai HH, Said SI. Hypoxia stimulates prostacyclin generation in dog lung in vitro. *Prostaglandins Leukot Med* 1982; 8: 311-306
61. Hambraeus-Jonzon K, Bindslev L, Mellgard AJ, Hedenstierna G. Hypoxic pulmonary vasoconstriction in human lungs. A stimulus-response study. *Anesthesiology* 1997; 86: 308-15
62. Hampl V, Cornfield DN, Cowan NJ, Archer SL. Hypoxia potentiates nitric oxide synthesis and transiently increases cytosolic calcium levels in pulmonary artery endothelial cells. *Eur Respir J* 1995; 8: 515-522
63. Hanley SP. Prostaglandins and the lung. *Lung* 1986; 164: 65
64. Hedenstierna G, Strandberg A, Brismar B. Functional residual capacity, thoracoabdominal dimensions, and central blood volume during general anesthesia with muscle paralysis and mechanical ventilation. *Anesthesiology* 1985; 62: 247
65. Hlastala MP, Bernard SL, Erickson HH, Fedde MR, Gaughan EM, McMurphy R, Emery MJ, Polissar N, Glenny RW. Pulmonary blood flow distribution in standing horses is not dominated by gravity. *J Appl Physiol* 1996; 81: 1051-1061
66. Hlastala MP, Glenny RW. Vascular structure determines pulmonary blood flow distribution. *News Physiol Sci* 1999; 14:182-186
67. Hlastala MP, Lamm WJE, Karp A, Polissar NL, Starr IR, Glenny RW. Spatial distribution of hypoxic pulmonary vasoconstriction in the supine pig. *J Appl Physiol* 2004; 96: 1589-1599
68. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. *Annu Rev Pharmacol Toxicol* 1999; 39: 191-220.
69. Hoepfer MM, Rubin LJ. Update in Pulmonary Hypertension. *Am J Respir Crit Care Med* 2006; 173: 499-505
70. Hogg JC, Holst P, Corry P, Ruff F, Housley E, Morris E. Effect of regional lung expansion and body position on pulmonary perfusion in dogs. *J Appl Physiol* 1971; 31: 97-101.
71. Ignarro LJ, Buga GM, Wood KS, Byrnes RE, Chandburri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. *Proc Natl Acad Sci USA* 1987; 84: 9265-9269
72. Ishikawa S. Oxygenation may improve with time during one-lung ventilation. *Anesth Analg* 1999; 89: 258

73. Johannigman JA, Davis K Jr, Miller SL, Campbell RS, Luchette FA, Frame SB, Branson RD. Prone positioning for acute respiratory distress syndrome in the surgical intensive care unit: who, when, and how long? *Surgery* 2000; 128: 708–716.
74. Jordan S, Mitchell JA, Quinlan GJ, Goldstraw P, Evans TW. The pathogenesis of lung injury following pulmonary resection. *Eur Respir J* 2000; 15: 790-799
75. Kadowitz PJ, Spannhake EW, Hyman AL. Prostaglandins evoke a whole variety of responses in the lung. *Environ Health Perspect* 1980; 35: 181
76. Kallet RH, Jasmer RM, Pittet JF, et al. Clinical implementation of the ARDS network protocol is associated with reduced hospital mortality compared with historical controls. *Crit Care Med* 2005; 33: 925-929
77. Kaneko K, Milic-Emili J, Dolovich MB Dawson A, Bates DV. Regional distribution of ventilation and perfusion as a function of body position. *J Appl Physiol* 1966; 21: 767-777
78. Kellow NH, Scott AD, White SA, Fenech RO. Comparison of the effects of propofol and isoflurane anaesthesia on right ventricular function and shunt fraction during thoracic surgery. *Br J Anaesth* 1995; 75: 578-82
79. Kerr LV, Aken HV, Vandermeersch E, Vermaut G, Lerut T. Propofol does not inhibit hypoxic pulmonary vasoconstriction in humans. *J Clin Anesth* 1989; 1: 248-8
80. Lamm WJE, Graham MM, Albert RK. Mechanism by which the prone position improves oxygenation in acute lung injury. *Am J Respir Crit Care Med* 1994; 150: 184-193
81. Langer M, Mascheroni D, Gattinoni L. The prone position in ARDS. A clinical study. *Chest* 1998; 94: 103-107
82. Larsson A, Malmkvist G, Werner O. Variations in lung volume and compliance during pulmonary surgery. *Br J Anaesth* 1987; 59: 585-591
83. Lohser J. Evidence-based management of one-lung ventilation. *Anesthesiology Clin* 2008;26:241-72
84. Lopez-Majano V, Data PG, Martignoni R, Lossredo B, Arborelius M Jr. Pulmonary blood flow distribution in erect man in air and during breathhold diving. *Aviat Space Environ Med* 1990; 61 :1107-15
85. Luckhoff A, Pohl U, Mulsch A, Busse R. Differential role of extra-and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. *Br J Pharmacol* 1988; 95: 189-196
86. Luhr O, Antonsen K, Karlsson M, et al. Incidence and mortality after respiratory failure and ARDS in Sweden, Denmark and Iceland. *Am J Respir Crit Care Med* 1999; 159: 1849-1861
87. Mancebo J, Fernandez R, Blanch L, Rialp G, Gordo F, Ferrer M, Rodriguez F, Garro P, Ricart P, Vallverdu I, Gich I, Castano J, Saura P, Dominguez G, Bonet A, Albert RK. A multicenter trial of prolonged prone ventilation in severe ARDS. *Am J Respi Crit Care Med* 2006; 173: 1233-1239

88. Marshall BE, Marshall C. Continuity of response to hypoxic pulmonary vasoconstriction. *J Appl Physiol* 1980;59:189-96
89. Marshall C, Lindgren L, Marshall BE. The effect of inhalation anaesthetics on HPV. *Anesthesiology* 1983; 59: A527
90. Marshall C, Marshall BE. Site and sensitivity for hypoxic pulmonary vasoconstriction. *J Appl Physiol* 1983;55:711-16
91. Martin M, Salim A, Murray J, et al. The decreasing incidence and mortality of acute respiratory distress syndrome after injury: a 5-year observational study. *J Trauma* 2005; 59: 1107-13
92. Melsom MN, Flatebø, T, Kramer-Johansen J, Aulie A, Sjaastad Ov, Iversen PO, Nicolaysen G. Both gravity and non-gravity dependent factors determine regional blood flow within the goat lung. *Acta Physiol Scand* 1995; 153: 343-53
93. Michelakis ED, Thebaud B, Weir EK, Archer SL. Hypoxic pulmonary vasoconstriction: redox regulation of O₂-sensitive K⁺-channels by a mitochondrial O₂-sensor in resistance artery smooth muscle cells. *J Mol Cell Cardiol* 2004; 37: 1119-36
94. Miller FL, Chen L, Malmqvist G, Marshall C, Marshall BE. Mechanical factors do not influence blood flow distribution in atelectasis. *Anesthesiology* 1989; 70: 481-8
95. Minami K, Fukuzawa K, Nakaya Y, Zeng XR, Inoue I. Mechanism of activation of the Ca²⁺-activated K⁺ channel by cyclic AMP in cultured porcine coronary artery smooth muscle cells. *Life Sci* 1993; 53: 1129-1135
96. Moncada S, Palmer RM Jr, Higgs EA. Biosynthesis of nitric oxide from L-arginine: A pathway for the regulation of cell function and communication. *Biochem Pharmacol*. 1989; 38: 1709-1715
97. Morcos E, Jansson OT, Wiklund NP. Bacillus Calmette-Guerin induces long-term local formation of nitric oxide in the bladder via the induction of nitric oxide synthase activity in urothelial cells. *J Urol* 2001; 165: 678-682
98. Moudgil R, Michelakis ED, Archer L. Hypoxic pulmonary vasoconstriction. *J Appl Physiol* 2005; 98: 390-403
99. Mure M, Domino KB, Lindahl SGE, Hlastala MP, Altemeier WA, Glenny RW. Regional ventilation-perfusion distribution is more uniform in the prone position. *J Appl Physiol* 2000; 88: 1076-1083
100. Mure M., Martling CR, Lindahl. SGE. Dramatic effect on oxygenation in patients with severe acute lung insufficiency treated in prone position. *Crit Care Med* 1994; 25: 1539-1544
101. Musch G, Layfield JD, Harris RS, Melo MF, Winkler T, Callahan RJ, Fischman AJ, Venegas JG. Topographical distribution of pulmonary perfusion assessed by PET in supine and prone humans. *J Appl Physiol* 2002; 93: 1841-1851

102. Mutoh T, Guest RJ, Lamm WJE, Albert RK. Prone position alters the effect of volume overload on regional pleural pressures and improves hypoxemia in pigs in vivo. *Am Rev Respir Dis* 1992; 146: 300-306
103. Mutoh T, Lamm WJE, Embree LJ, Hildebrandt J, Albert RK. Abdominal distension alters regional pleural pressures and chest wall mechanics in pigs in vivo. *J Appl Physiol* 1991; 70(6): 2611-2618
104. Nyrén S, Mure M, Jacobsson H, Larsson SA, Lindahl SGE. Pulmonary perfusion is more uniform in the prone than in the supine position: scintigraphy in healthy humans. *J Appl Physiol* 1999; 86: 1135-1141
105. Olschewski H, Ghofrani HA, Walrath D, Schermuly R, Temmedfeld-Wollbruck B, Grimminger F, Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. *Am J Respir Crit Care Med* 1999; 160(2): 600-607
106. Oparil S, Chen SJ, Meng QC, Elton TS, Yano M, Chen YF. Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. *Am J Physiol Lung Cell Mol Physiol* 1995; 268: 95-100
107. Opitz CF, Wenzel R, Bettman M, Schaffarczyk R, Linscheid M, Hetzer R, Ewert R. Assessment of the vasodilator response in primary pulmonary hypertension. *European Heart Journal* 2003; 24: 356-365
108. Orphanidou D, Hughes JM, Myers MJ, Al-Suhali A-R, Henderson B. Tomography of regional ventilation and perfusion using krypton 81m in normal subjects and asthmatic patients. *Thorax* 1986; 41: 542-551.
109. Ozcan PE, Sentürk M, Sungur Ulke Z, Toker A, Dilege S, Ozden E, Camci E. Effects of thoracic epidural anesthesia on pulmonary venous admixture and oxygenation during one-lung ventilation. *Acta Anaesthesiol Scand* 2007; 51: 1117-22
110. Palmer RMJ, Moncada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. *Biochem Biophys Res Commun* 1989; 158: 348-52
111. Pelletier N, Robinson NE, Kaiser L, Derksen FJ. Regional differences in endothelial function in horse lungs: possible role in blood flow distribution? *J Appl Physiol* 1998; 85: 537-542
112. Pelosi P, Brazzi L, Gattinoni L. Prone position in acute respiratory distress syndrome. *Eur Respir J* 2002; 20: 1017-1028
113. Pelosi P, Croci M, Calappi E, et al. The prone positioning during general anesthesia minimally affects respiratory mechanics while improving functional residual capacity and increasing oxygen tension. *Anesth Analg* 1995; 80:955-960
114. Pelosi P, Tubiolo D, Mascheroni D, Vicardi P, Crotti S, Valenza F, Gattinoni L. Effects of the prone position on respiratory mechanics and gas exchange during acute lung injury. *Am J Respir Crit Care Med* 1998; 157: 387-393

115. Pérez-Vizcaíno F, Villamor E, Duarte J, Tamargo J. Involvement of protein kinase C in reduced relaxant responses to the NO/cyclic GMP pathway in piglet pulmonary arteries contracted by the thromboxane A₂-mimetic U46619. *Br J Pharmacol* 1997; 121:1323-1333
116. Persson MG, Lönnqvist PA, Gustafsson LE. Positive end-expiratory pressure ventilation elicits increases in endogenously formed nitric oxide as detected in air exhaled by rabbits. *Anesthesiology* 1995; 82: 969-974
117. Petersson J, Rohdin M, Sanchez-Crespo A, Neraldik B, Nyrén S, Jacobsson H, Larsson SA, Lindahl SGE, Linnarsson D, Polissar N, Glenn RW, Mure M. Paradoxical redistribution of pulmonary blood flow in prone and supine humans exposed to hypergravity. *J Appl. Physiol* 2006; 100: 240-248
118. Petersson J, Rohdin M, Sanchez-Crespo A, Neraldik B, Nyrén S, Jacobsson H, Larsson SA, Lindahl SGE, Linnarsson D, Polissar N, Glenn RW, Mure M. Posture primarily affects the distribution of lung tissue with minor effect on regional blood flow and ventilation. *Respiratory Physiology & Neurobiology* 2007; 156: 293-303
119. Petersson J, Rohdin M, Sanchez-Crespo A, Neraldik B, Nyrén S, Jacobsson H, Larsson SA, Lindahl SGE, Linnarsson D, Polissar N, Glenn RW, Mure M. Regional lung blood flow and ventilation in upright humans studied with quantitative SPECT. *Respiratory Physiology & Neurobiology* 2009; 166: 54-60
120. Pohl U, Herlan K, Huang A, Bassenge E. EDRF-mediated shear-induced dilation opposes myogenic vasoconstriction in small rabbit arteries. *Am J Physiol* 1991; 261: H2016-2023
121. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Ferguson ND. Has mortality from ARDS decreased over time?: A systematic review. *Am J Respir Crit Care Med* 2009; 179(3): 220-227
122. Pizov R, Weiss YG, Oppenheim-Eden A, Glickman H, Goodman S, Koganov Y, Barak V, Merin G, Kramer MR. High oxygen concentration exacerbates cardiopulmonary bypass induced lung injury. *J Cardiothorac Vasc Anesth* 2000; 14(5): 519-23
123. Prisk GK, Guy HJ, Elliott AR, West JB. Inhomogeneity of pulmonary perfusion during sustained microgravity on SLSS-1. *J Appl Physiol* 1994; 76: 1730-1738
124. Prisk GK, Yamada K, Henderson C, Arai TJ, Levin DL, Buxton RB, Hopkins SR. Pulmonary perfusion in the prone and supine postures in the normal human lung. *J Appl Physiol* 2007; 103: 883-894
125. Reed JH, Wood EH. Effect of body position on vertical distribution of pulmonary blood flow. *J Appl Physiol* 1970; 28: 303-311
126. Rees ID, Gaines GY. One-lung anaesthesia-a comparison of pulmonary gas exchange during anaesthesia with ketamine and enflurane. *Anesth Analg* 1984; 63: 521-5
127. Remillard Cv, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin LJ, O'connor DT, Yuan JX. Function of Kv1.5

- channels and genetic variations of KCNA5 in patients with pulmonary arterial hypertension. *Am J Physiol Cell Physiol* 2007; 292(5): C 1837-53
128. Rhodin M, Pettersson J, Sundblad P, Mure MJ, Glenny RW, Lindahl SG, Linnarsson D. Effects of gravity on lung diffusion capacity and cardiac output in prone and supine humans. *J Appl Physiol* 2003; 95: 3-10
129. Richter T, Bellani G, Harris RC, Marcos FVM, Winkler T, Venegas JG, Musch G. Effect of prone position on regional shunt, aeration and perfusion in experimental acute lung injury. *Am J Respir Crit Care Med* 2005; 172: 480-487
130. Riley RL, Lilienthal JL, Proemmel DD, Franke RE. On the determination of the physiologically effective pressures of oxygen and carbon dioxide in alveolar air. *Am J Physiol* 1946; 147:191
131. Reeves JT, van Grondelle A, Voelkel NF. Prostacyclin production and lung endothelial cell shear-stress. *Prog Clin Biol Res* 1983; 136: 125
132. Robinson C, Hardy CC, Holgate ST. Pulmonary synthesis, release, and metabolism of prostaglandins. *J Allergy Clin Immunol* 1985; 76: 265
133. Salter M, Knowles RG, Moncada S. Widespread tissue distribution, species distribution and changes in activity of Ca²⁺-dependent and Ca²⁺-independent nitric oxide synthases. *FEBS Lett* 1991; 291: 145-149
134. Sánchez-Crespo A, Petersson J, Nyrén S, Mure M, Glenny RW, Thorell JO, Jacobsson H, Lindahl SGE, Larsson SA. A novel quantitative dual-isotope method for simultaneous ventilation and perfusion lung SPECT. *Eur J Nucl Med Mol Imaging* 2002; 29: 863-875
135. Scheuch G, Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptides. *Journal of Physiology and Pharmacology* 2007; 58 Suppl 5: 615-625
136. Shimoda LA, Sham JS, Sylvester JT. Altered pulmonary vasoreactivity in the chronically hypoxic lung. *Physiol Res* 2000; 49: 549-560
137. Slutsky AS. The acute respiratory distress syndrome, mechanical ventilation and the prone position. *N Engl J Med* 2001; 345: 610-611
138. Sprague RS, Stephenson AH, Olearczyk JJ, Longiro AJ. COX and the control of pulmonary circulation. *Thromb Res* 2003; 110(5-6): 335-338
139. Starr IR, Lamm WJ, Neradilek B, et al. Regional hypoxic pulmonary vasoconstriction in prone pigs. *J Appl Physiol* 2005; 99(1): 363-70
140. Stephenson AH, Longiro AJ, Holmberg SW, et al. Eicosanoid balance and perfusion redistribution of oleic acid-induced acute lung injury *J Appl Physiol* 1992; 73(5): 2126-2134
141. Stuehr DJ. Mammalian nitric oxide synthases. *Biochim Biophys Acta* 1999; 1411: 217-230
142. Talbot NP, Balanos GM, Dorrington KL, Robbins PA. Two temporal components within the human pulmonary vascular response to 2 h of isocapnic hypoxia. *J Appl Physiol* 2005; 98: 1125-1139

143. Tamaoki J, Chiyotani A, Takeyama K, Yamaguchi F, Konno K. Relaxation and inhibition of contractile response to electrical field stimulation by Beraprost sodium in canine airway smooth muscle. *Prostaglandins* 1993; 45(4):363-373
144. Thomas HM, Garrett RC. Strength of hypoxic pulmonary vasoconstriction determines shunt fraction in dogs with atelectasis. *J Appl Physiol* 1982; 53:44-51
145. Tokics L, Hedenstierna G, Svensson L, Brismar B, Cederlund T, Lundquist H, Strandberg A. V'/Q' distribution and correlation to atelectasis in anesthetized paralyzed humans. *J Appl Physiol* 1996; 81: 1822-1833
146. Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. *Intensive Care Med* 2006; 32:24-33
147. Treppo MJ, Mijailovich SM, Venegas JG. Contributions of pulmonary perfusion and ventilation to heterogeneity in V (A)/Q measured by PET. *J Appl Physiol* 1997; 82: 1163-1176
148. Triantafilou AN, Benumof JL, Lecamwasam HS. Physiology of the lateral decubitus position, the open chest and one-lung ventilation. Kaplan JA, Slinger PD. *Thoracic anesthesia*. 3rd edition, Elsevier Science (USA) 2003; 71-94
149. Twort CH, van Breemen C. Cyclic guanosine monophosphate-enhanced sequestration of Ca²⁺ by sarcoplasmic reticulum in vascular smooth muscle. *Circ Res* 1988; 62(5): 961-964
150. Usmani OS, Biddiscombe MF, BarnesPJ. Regional lung deposition and bronchodilator response as a function of beta 2-agonist particle size. *Am J Respir Crit Care Med* 2005; 172(12): 1497-1504
151. Vaandrager AB, de Jonge HR, Signalling by cGMP-dependent protein kinases. *Mol Cell Biochem* 1996; 157: 23-30
152. Valanne J, Korttila K, Ylikorkala O. Intravenous diclofenac sodium decreases prostaglandin synthesis and postoperative symptoms after general anaesthesia in outpatients undergoing dental surgery. *Acta Anaesthesiol Scand* 1987; 31(8): 722-727
153. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. *Am J Respir Crit Care Med* 1996; 153(3): 991-996
154. Walther SM, Domino KB, Hlastala MP. Effects of posture on blood flow diversion by hypoxic pulmonary vasoconstriction in dogs. *British Journal of Anaesthesia* 1998; 81: 425-429
155. Walther SM, Domino KB, Glenny RW, Polissar NL, Hlastala MP. Pulmonary blood flow distribution has a hilar-to-peripheral gradient in awake, prone sheep *J Appl Physiol* 1997; 82: 678-685.
156. Vane JR. Nobel lecture. Adventures and excursions in bioassay: the stepping stones to prostacyclin. *Postgrad Med J* 1983; 59: 743-758

157. Wang Y, Marsden PA. Nitric oxide synthases : Biochemical and molecular regulation. *Curr Opin Nephrol Hypertens* 1995; 4: 12-22
158. Venegas JG, Yamada Y, Burnham C, et al. Local gas transport in eucapnic ventilation: effects of gravity and breathing frequency. *J Appl Physiol* 1990; 68: 2287-2295
159. Venet C, Guymarc'h S, Zeni F, et al. The oxygenation variations related to prone positioning during mechanical ventilation: a clinical comparison between ARDS and non-ARDS hypoxemic patients. *Intensive Care Med* 2001; 27: 1352-1359
160. Venet C, Guymarc'h S, Pingat J, Michard C, Laporte S, Bertrand M, Gery P, Page D, Vermesch R, Bertrand JC, Zeni F. Prognostic factors in acute respiratory distress syndrome: a retrospective multivariate analysis including prone positioning in management strategy. *Intensive Care Med* 2003; 29: 1435-1441
161. Weir EK, Archer SL. The mechanisms of acute hypoxic pulmonary vasoconstriction: the tale of two channels. *FASEB J* 1995; 9: 183-189
162. West JB, Dollery CT, Naimark A. Distribution of blood flow in isolated lung: relation to vascular and alveolar pressures. *J Appl Physiol* 1964; 19: 713-724
163. von Euler US, Liljestrand G. Observations on the pulmonary arterial blood pressure in the cat. *Acta Physiol Scand* 1946; 12: 301-320
164. Zweier JL, Samouilov A, Kuppusamy P. Non-enzymatic nitric oxide synthesis in biological systems. *Biochem Biophys Acta* 1999; 1411: 250-262
165. Yamaguchi K, Mori M, Kawai A, Asano K, Takasugi T, Umeda A, Yokoyama T. Attenuation of hypoxic pulmonary vasoconstriction in acute oleic acid lung injury- significance of vasodilator prostanoids. *Adv Exp Med Biol* 1992; 316: 219-309